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5ABSTRACT
The diagnosis of coeliac disease is currently based on the demonstration of small-
bowel mucosal villous atrophy and crypt hyperplasia. However, the mucosal damage
develops gradually and patients may evince clinical symptoms even before the villous
atrophy develops. In addition, there are extraintestinal forms of coeliac disease in
which the intestinal damage can be milder or even absent. These observations suggest
that the current diagnostic criteria are insufficient to cover the wide range of gluten-
dependent disorders. The early mucosal changes are too ambivalent for the diagnosis
as such, but evidence would indicate that specific coeliac antibodies may also appear
prior to villous atrophy. The primary aim in the present study was to establish whether
adults and children having positive endomysial antibodies (EmA) suffer from a
coeliac-type disorder and would benefit from dietary treatment while still showing
normal small-bowel mucosal morphology.
The dissertation comprised altogether four separate clinical studies. Study I was a
randomized clinical trial involving 70 EmA-positive adults and 34 EmA-negative
controls. At baseline, the small-bowel mucosal structure and inflammatory markers,
serum coeliac antibodies, clinical symptoms, coeliac disease-associated genotype and
laboratory parameters were evaluated in all. A total of 23 EmA-positive subjects were
found to have normal mucosal morphology and thus did not fulfil the current
diagnostic criteria for coeliac disease. They were randomized either to continue on a
normal diet or to start a gluten-free diet. The remaining 47 EmA-positive subjects had
villous atrophy and started gluten-free dietary treatment. Finally, after one year on trial
all EmA-positive participants were re-evaluated. Study II comprised 27 EmA-positive
adults with normal mucosal morphology and 46 with villous atrophy. Together with
serological and histological evaluations, self-rated gastrointestinal symptoms, health-
related quality of life, bone mineral density (BMD) and body mass index (BMI) were
measured both at baseline and after one year on a gluten-free diet. Altogether 110
healthy adults served as non-coeliac controls. The cohort in study III comprised 17
EmA-positive children having normal villi, 42 children with villous atrophy and 17
EmA-negative controls. After baseline eight EmA-positive children with normal villi
continued with a normal diet and five were placed on a gluten-free diet by their
parents` decision. Again, all EmA-positive children were re-investigated after one year
6on trial. Finally, study IV involved three subjects who had coeliac disease with
classical gastrointestinal symptoms diagnosed during childhood, but who at some point
re-introduced gluten in their diet and after a very long asymptomatic period were
remitted to hospital on suspicion of dermatitis herpetiformis.
The results of the prospective studies (I-III) were analogous and showed that both
EmA-positive adults and children may manifest clinical symptoms and even decreased
BMD despite normal small-bowel mucosal structure. In addition, in the EmA-positive
subjects who continued on a gluten-containing diet the mucosal changes were
exacerbated, coeliac antibody levels increased and clinical symptoms persisted,
whereas in those who started treatment the antibodies decreased and clinical symptoms
were alleviated. The gluten-dependency of these EmA-positive subjects was further
supported by the fact that all had the HLA genotype required for coeliac disease. In
Study II it was shown that a gluten-free diet may alleviate depression and is not
detrimental to the quality of life of EmA-positive subjects with normal villi. The
treatment may also improve BMD and would appear not to affect the weight control of
these EmA-positive subjects. Finally, skin biopsy in the three cases in Study IV
confirmed the diagnosis of dermatitis herpetiformis and showed that the coeliac
disease phenotype may change after a long asymptomatic period. In addition, although
they had no abdominal symptoms and only partial villous atrophy, all three cases had
coeliac antibodies in the serum and coeliac-type autoantibody deposition in the
intestinal mucosa.
The results of the present series demonstrated that EmA-positive subjects suffer
from a gluten-dependent disorder similar to coeliac disease and benefit from treatment
despite normal small-bowel mucosal morphology. Furthermore, the clinical and
histological presentation of coeliac disease may change over time, showing that the
intestinal and extraintestinal forms of the disorder belong to the same category of
genetic gluten intolerance. These observations indicate that the current diagnostic
criteria for coeliac disease are inadequate and should be revised. In the future more
studies are needed to assess whether EmA-positive but asymptomatic patients having
normal mucosal morphology should be treated and further, to assess the role of
endoscopic studies in the diagnosis of coeliac disease.
7TIIVISTELMÄ
Keliakian nykyiset diagnostiset kriteerit edellyttävät ohutsuolen limakalvon
suolinukkavaurion osoittamista. Limakalvovaurio kuitenkin kehittyy asteittain, ja
potilaat saattavat kärsiä tyypillisistä keliakiaoireista suolinukkarakenteen ollessa vielä
normaali. Lisäksi keliakia saattaa esiintyä myös suoliston ulkopuolisina oireyhtyminä,
joissa limakalvomuutokset voivat olla lieviä tai puuttua kokonaan. Havainnot
viittaavat siihen, että nykyiset diagnostiset kriteerit eivät riitä kattamaan
gluteeniriippuvaisten sairauksien laajaa kirjoa. Toisaalta ohutsuolen limakalvon
varhaiset muutokset ovat liian epäspesifinen löydös lopullisen keliakiadiagnoosin
asettamiseksi. On kuitenkin alustavaa näyttöä, että keliakiaspesifejä vasta-aineita voi
esiintyä seerumissa jo ennen suolinukkavaurion kehittymistä. Tämän tutkimuksen
tarkoituksena oli arvioida kärsivätkö endomysiinivasta-ainepositiiviset (EmA)
henkilöt, joilla on vielä normaali suolinukkarakenne gluteeniriippuvaisesta sairaudesta,
sekä hyötyvätkö he varhain aloitetusta keliakian ruokavaliosta.
Väitöskirjatyö koostui kaikkiaan neljästä erillisestä osatyöstä. Osatyö I oli
satunnaistettu seurantatutkimus, mihin osallistui yhteensä 70 EmA-positiivista aikuista
ja 34 EmA-negatiivista verrokkia. Tutkimuksen alussa osallistujille tehtiin laajat
histologiset, serologiset ja kliiniset tutkimukset, sekä määritettiin keliakiaan liittyvät
perintötekijät. Alkututkimusten perusteella 23 EmA-positiivisella henkilöllä oli vielä
normaali suolinukkarakenne. Nämä henkilöt satunnaistettiin joko jatkamaan entisellä
ruokavaliollaan tai aloittamaan gluteenivapaa ruokavalio. Lopuilla 47 EmA-
positiivisella tutkittavalla todettiin diagnostinen suolinukkavaurio, ja he aloittivat
ruokavaliohoidon. Vuoden seurannan jälkeen alkuvaiheen tutkimukset toistettiin
kaikille EmA-positiivisille osallistujille. Osatyössä II oli kaikkiaan 27 EmA-
positiivista aikuista joilla oli normaali suolinukkarakenne, sekä 46 tutkittavaa joilla oli
diagnostinen limakalvovaurio. Laajojen histologisten ja serologisten tutkimusten
lisäksi osallistujilta määritettiin myös itsearvioidut kliiniset oireet ja terveyteen liittyvä
elämänlaatu, sekä mitattiin luuntiheys ja painoindeksi. Yhteensä 110 tervettä aikuista
toimi tutkimuksen vertailuryhmänä. Osatyö III koostui 17 EmA-postiivisesta lapsesta
8joilla oli normaali suolinukka, 42 lapsesta joilla oli suolinukkavaurio, sekä 17 EmA-
negatiivisesta verrokista. Alkututkimusten jälkeen viisi EmA-positiivista lasta joilla oli
normaali suolinukka sekä lapset joilla oli suolinukkavaurio aloittivat gluteenivapaan
ruokavalion. Kahdeksan normaalin suolinukan omaavaa EmA-positiivista lasta jatkoi
gluteenipitoisella ruokavaliolla. Vuoden seurannan jälkeen kaikki alkuvaiheen
tutkimukset toistettiin. Osatyö IV käsitti kolme henkilöä, joilla oli todettu sekä
suolinukkavaurio että tyypilliset keliakiaoireet lapsuudessa. Myöhemmin kyseiset
henkilöt olivat kuitenkin aloittaneet uudelleen gluteenin käytön, ja pitkän oireettoman
ajan jälkeen heidät lähettiin sairaalaan ihokeliakiaepäilyn vuoksi.
Seurantatutkimusten (I-III) tulokset osoittivat, että EmA-positiivisilla henkilöillä
voi olla keliakiaoireita ja jopa heikentynyt luuntiheys suolinukan ollessa vielä
normaali. Lisäksi gluteeninkäyttöä jatkettaessa potilaiden limakalvovaurio paheni,
keliakiavasta-ainetasot nousivat ja kliiniset oireet jatkuivat, kun taas ruokavaliohoidon
aikana vasta-ainetasot laskivat ja oireet lievittyivät. EmA-positiivisten henkilöiden
samankaltaisuutta riippumatta suolinukkavaurion asteesta osoitti myös heiltä jokaiselta
todetut keliakiaan sopivat HLA-perintötekijät. Osatyön II tulokset osoittivat
gluteenivapaan ruokavalion myös lievittävän EmA-positiivisten potilaiden
masennusoireita, sekä mahdollisesti parantavan luuntiheyttä jälleen huolimatta
normaalista suolinukkarakenteesta. Tulosten perusteella keliakian varhainen hoito ei
myöskään huononna  EmA-positiivisten aikuisten elämänlaatua tai painonhallintaa.
Lopuksi, kaikki kolme potilasta osatyössä IV saivat ihokeliakiadiagnoosin, osoittaen
että pitkän oireettoman ajanjakson jälkeen keliakian kliininen ja histologinen ilmiasu
voivat vaihtua. Lisäksi näillä potilailla todettiin sekä keliakiavasta-aineita seerumissa
että keliakiatyyppiset autovasta-ainekertymät ohutsuolen limakalvolla.
Väitökirjatyön tulokset osoittavat EmA-positiivisten henkilöiden kärsivän
perinnöllisestä gluteeniherkästä sairaudesta riippumatta ohutsuolen limakalvovaurion
asteesta. Lisäksi sekä keliakian kliininen että histologinen taudinkuva voivat muuttua
ajan kuluessa, osoittaen klassisen suolioireisen keliakian ja suoliston ulkopuolisen
ihokeliakian edustavan saman gluteeniherkän sairauden eri ilmenemismuotoja.
Löydösten perusteella keliakian nykyiset diagnostiset kriteerit ovat riittämättömät ja
tulisi uudistaa. Tulevaisuudessa tarvitaan vielä lisätutkimuksia päätettäessä tulisiko
keliakiavasta-ainepositiivisia täysin oireettomia henkilöitä hoitaa, sekä arvioitaessa
ohutsmmuolen tähystystutkimusten asemaa keliakian diagnostiikassa.
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ABBREVIATIONS
AGA antigliadin antibodies
APC antigen-presenting cell
ARA anti-reticulin antibodies
BMI body mass index
BMD bone mineral density
CI confidence interval
CD Cluster design
CrD crypt depth
ELISA enzyme-linked immunosorbent assay
EmA endomysial antibodies
ESPGAN  European Society of Paediatric Gastroenterology and Nutrition
GSRS Gastrointestinal Symptom Rating Scale
HLA human leukocyte antigen
IEL intraepithelial lymphocyte
Ig immunoglobulin
IL interleukin
INF interferon
ND no data
PGWB Psychological General Well-Being
SF-36 Short Form 36 Health Survey
TG transglutaminase
TG2-ab transglutaminase 2 antibody
TNF tumour necrosis factor
U unit value
Vh villous height
WHO World Health Organisation
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INTRODUCTION
Coeliac disease is a common autoimmune-based disorder caused by ingested gluten in
genetically predisposed individuals. The classical symptoms are abdominal
complaints, diarrhoea and malabsorption (Gee 1888, Visakorpi et al. 1970), but the
clinical symptoms can be heterogeneous and may appear at any age (Mäki et al. 1988a,
Murray et al. 2003). The current diagnostic criteria are based on the demonstration of
small-bowel mucosal villous atrophy and crypt hyperplasia (Walker-Smith et al.
1990). However, this intestinal damage develops gradually from completely normal
mucosa to overt villous atrophy (Marsh 1992) and the deterioration may take years or
even decades (Mäki et al. 1990, Lähdeaho et al. 2005). A number of studies have
shown that patients may suffer from gluten-dependent symptoms or even
complications of coeliac disease before villous atrophy develops (Egan-Mitchell et al.
1981, Collin et al. 1992, Kaukinen et al. 1998, Salmi et al. 2006) and there are also
indications that patients may benefit from early treatment with a gluten-free diet even
when the mucosal structure is normal (Picarelli et al. 1996a, Kaukinen et al. 2001,
Paparo et al. 2005). These results suggest that the current diagnostic criteria for coeliac
disease are inadequate and should be revised.
Only a minority of patients with mild small-bowel mucosal changes will eventually
develop coeliac disease (Ferguson and Murray 1971, Kuitunen et al. 1982, Kakar
2003, Lähdeaho et al. 2005), and more specific diagnostic methods for early-
developing disease are required. During recent decades sensitive and specific
endomysial (EmA) and transglutaminase 2 antibodies (TG2-abs) have been
increasingly applied in case-finding and as a result subjects with positive antibodies
but morphologically normal mucosal villi are frequently detected (Mäki et al. 2003,
Fasano et al. 2003). Previously such cases were considered false-positive, but there is
evidence that the antibodies may actually predict forthcoming villous atrophy and
could be used for an early diagnosis of coeliac disease (Mäki et al. 1991b, Collin et al.
1993, Troncone 1995, Salmi et al. 2006). At present, however, randomized and
controlled follow-up trials of the treatment of these antibody-positive patients with
15
normal small-bowel mucosal villous morphology are lacking and there is no consensus
regarding their diagnosis.
The purpose of the present study was to investigate the natural history of coeliac
disease in EmA-positive adults and children with normal small-bowel mucosal villous
structure. After baseline investigation these EmA-positive subjects either continued
with a gluten-containing diet or were placed on an experimental gluten-free diet and
were evaluated using a number of clinical, histological and serological markers of
coeliac disease. Finally, all results were compared with those obtained in subjects with
overt villous atrophy and in non-coeliac controls. In addition, changes in the clinical
and histological presentation of coeliac disease over time was investigated in three
patients in whom the classical intestinal disorder with small-bowel mucosal villous
atrophy had been diagnosed during childhood but who subsequently resumed a gluten-
containing diet.
16
REVIEW OF THE LITERATURE
1. HISTORY OF COELIAC DISEASE
For most of the history of humankind coeliac disease has apparently been a very rare
condition (Guandalini 2008). Gluten, the causative agent, is present only in certain
cereals which were virtually non-existent in the diet of the early hunter-gatherer
societies. Thus, coeliac disease could have evolved only after the development of
agriculture in the fertile crescents of South East Asia about 10000 years ago. Even
then, the spread of cultivation took thousands of years and, up to the last few centuries,
the grains also contained relatively low amounts of gluten. This historical background
perhaps explains the conspicuous lack of medical reports of coeliac disease before the
last few centuries. Although the Greek physician Aretaeus of Cappadocia provided the
first known description about two thousand years ago (Adams 1856), the first medical
article appeared as late as 1815 (Baillie 1815) and the earliest systematic report was
written by Samuel Gee (1888) just over a hundred years ago.
Although a variety of dietary treatments were attempted during the first half of the
20th century, the actual cause of coeliac disease was unknown and it was often lethal,
particularly in children. It was thus a remarkable breakthrough when in the early 1950s
it was shown that the trigger of coeliac disease is wheat gluten (Dicke et al. 1953).
Soon these after the small-bowel mucosal damage was discovered (Paulley 1954) and
several new theories on the pathogenesis began to emerge. In the 1970s the association
of coeliac disease with certain genotypes was observed (Stokes et al. 1972) and the
wide clinical spectrum and extraintestinal forms of the disorder became evident.
During the last few decades the understanding of the pathogenesis has greatly
increased and population-based screening studies have revealed that coeliac disease is
one of the commonest chronic diseases in the Western world (Mäki et al. 2003, Fasano
et al. 2003, Lohi et al. 2007).
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2. CLINICAL FEATURES OF COELIAC DISEASE
2.1 Classical gastrointestinal manifestations
What Samuel Gee described as a paediatric disorder with gradual onset of steatorrhea
and malnutrition was regarded as the primary manifestation of coeliac disease for
almost a hundred years (Gee 1888). Patients often had deficiencies of important trace
elements such as iron, calcium, zinc, folate and vitamin B12, and common
complications were anaemia, rickets, poor growth, short stature and delayed puberty
(Visakorpi et al. 1970, Verkasalo et al. 1978, Mäki et al. 1988a). Although coeliac
patients may still evince all these symptoms and complications, it was realized in the
1980s that the clinical presentation is markedly variable and that intestinal symptoms
are not always present. Subsequently, older cases and those with milder symptoms
were increasingly being recognized (Logan et al. 1983, Mäki et al. 1988a), and
nowadays most coeliac patients either suffer from some extraintestinal manifestation
or have no symptoms at all (Collin et al. 1997, Murray et al. 2003).
2.2 Extraintestinal manifestations and complications
2.2.1 Dermatitis herpetiformis
Dermatitis herpetiformis is a skin form of coeliac disease (Duhring 1884). It has the
same genetic background as the intestinal disease (Katz et al. 1972, Spurkland et al.
1997) and coeliac antibodies are also present in most untreated dermatitis
herpetiformis patients (Reunala 2001). The two forms of the disease are associated
with the same autoimmune disorders and share many complications such as decreased
bone mineral density (BMD) (DiStefano et al. 1999), certain malignancies (Collin et
al. 1996a, Askling et al. 2002) and dental enamel defects (Aine 1996). The skin
disorder is rare in childhood, the mean age at onset being usually between 30 and 40
years with a slight male predominance, and the characteristic clinical presentation is a
blistering rash on elbows and knees, though the rash can appear in all body areas
(Reunala 2001). Most dermatitis herpetiformis patients also have either villous atrophy
or at least inflammatory changes in the small-bowel mucosa (Marks et al. 1966,
18
Savilahti et al. 1992), but only a minority suffer from the gastrointestinal symptoms
typical of coeliac disease (Reunala 2001).
2.2.2 Other extraintestinal manifestations
Neurological symptoms and complications are common in untreated coeliac disease.
Hadjivassiliou and associates (1996) described a series of patients with ataxic
symptoms and positive coeliac antibodies, and this so-called gluten ataxia was later
taken to refer to subjects with unexplained ataxia and antibodies against gluten-derived
gliadin. Although less than half of these cases have small-bowel mucosal villous
atrophy, they have the HLA-type characteristic of coeliac disease and may respond to
dietary treatment (Hadjivassiliou 2008a). An increased prevalence of epilepsy has also
been associated with coeliac disease (Cooke and Smith 1966, Chapman et al. 1978),
but the risk would appear to be fairly modest (Luostarinen et al. 1999). There is even a
specific syndrome of epilepsy, cerebral calcifications and coeliac disease (Visakorpi et
al. 1970, Gobbi et al. 1992), but for some reason it occurs almost exclusively in certain
limited areas in Italy and Spain (Gobbi et al. 1992). In addition, some neuromuscular
disorders and an early-onset dementia have been connected to coeliac disease, but their
true prevalence remains to be elucidated (Cooke and Smith 1966, Hadjivassilou et al.
1997, Collin et al. 1991).
Coeliac patients may also suffer from severe psychiatric problems such as
irritability, anxiety, depression and schizophrenia (Goldberg 1970, Kalaydjian et al.
2009). Particularly depression seems to be common in both adults and adolescents
with coeliac disease (Hallert and Aström 1982, Pynnönen et al. 2004, Ludvigsson et al.
2007), although it has recently been suggested that depression is increased mainly in
patients having some co-morbidity such as type 1 diabetes mellitus (Garud et al. 2009).
Coeliac disease may be a contributing factor in many gynaecological and obstetrical
disorders such as infertility (Morris et al. 1970, Collin et al. 1996b), delayed menarche,
amenorrhoea and early menopause (Ferguson et al. 1982, Smecuol et al. 1996).
Furthermore, increased risks of miscarriages, prematurity, intrauterine growth
retardation and low birth weight have been reported (Joske and Martin 1971, Ciacci et
al. 1996, Gasbarrini et al. 2000, Martinelli et al. 2000). On the other hand, there are
also controversial results showing no increase in either unexplained infertility or
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pregnancy complications despite untreated coeliac disease (Kolho et al. 1999, Grego et
al. 2004, Tata et al. 2005).
Liver abnormalities are common and may appear either with or without other
clinical symptoms of coeliac disease, and even in children (Hagander et al. 1977,
Bardella et al. 1995, Farre et al. 2002). The hepatic injury seems to be gluten-sensitive
and its severity may vary from only slightly elevated transaminases to severe liver
failure requiring transplantation (Hagander et al. 1977, Bardella et al. 1995, Kaukinen
et al. 2002).
Other frequently observed extraintestinal manifestations of coeliac disease are
permanent dental enamel defects (Aine et al. 1996), recurrent aphthous ulcerations
(Ferguson et al. 1976), arthritis (Mäki et al. 1988b, Collin et al. 1992) and alopecia
areata (Corazza et al. 1995a).
2.2.3 Malignancies
The most severe complications of coeliac disease are certain malignancies. Previously,
when adult patients were rarely diagnosed and often inadequately treated, the risk
particularly of non-Hodgkin lymphomas was considered to be substantial (Holmes et
al. 1989). However, in recent studies the relative risk of these rather uncommon
malignancies has been only about two to six times higher than in the healthy
population (Collin et al. 1996a, Askling et al. 2002, West et al. 2004a, Viljamaa et al.
2006). Nevertheless, it is possible that long diagnostic delay or poor adherence to a
gluten-free diet increases the risk of intestinal lymphomas (Freeman 2004), and
especially so-called refractory coeliac disease seems to be a predisposing factor (Al-
Toma et al. 2006a). Coeliac disease has also been connected to other malignancies
such as oesophageal, large-intestine and liver cancers (Holmes et al. 1976, Askling et
al. 2002, West et al. 2004a), but the findings are somewhat controversial (Viljamaa et
al. 2006). For some unknown reason coeliac patients may have a reduced risk of lung
and breast cancers (West et al. 2004a, Viljamaa et al. 2006).
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2.2.4 Bone in coeliac disease
The association between bone disorders and coeliac disease has long been known
(Salvesen and Boe 1953), but the formerly common osteomalacia is nowadays rare and
osteoporosis is the most common complication at least in developed countries
(Valdimarsson et al. 1994). Dual energy X-ray absorptiometry (DEXA) has shown that
decreased BMD is common both in untreated children (Mora et al. 1993, Tau et al.
2006) and in adults with coeliac disease (Caraceni et al. 1988, Mazure et al. 1994,
Valdimarsson et al. 1994, Corazza et al. 1995b). In addition, untreated run an
approximately two- to four-fold risk of osteoporotic fractures compared with the
healthy population (Vasquez et al. 2000, West et al. 2003a). The pathophysiological
mechanisms underlying the bone loss involved are somewhat obscure, but it is evident
that small-bowel mucosal damage reduces intestinal calcium and vitamin D absorption
and thus leads to secondary hyperparathyroidism and bone resorption (Corazza et al.
1995b). This notwithstanding, osteoporosis can be present even while the villous
structure is still morphologically normal (Mustalahti et al. 1999, Kaukinen et al. 2001),
and it has been suggested that mucosal inflammation affects bone loss by disturbing
the normal balance of bone remodelling (Taranta et al. 2004). Furthermore, antibodies
against skeletal transglutaminase (TG) (Sugai et al. 2002) or osteoclastic regulator
osteoprotegerin (Riches et al. 2009) may contribute to bone deterioration.
2.2.5 Coeliac disease and quality of life
The health-related quality of life comprises many physical, social and emotional
dimensions, and includes an overall satisfaction with life and a general sense of well-
being (Usai et al. 2002). Reproducible and validated methods should be used when
quantifying the effect of a disease on the quality of life, and in coeliac disease research
mostly generic questionnaires such as Psychological General Well-Being (PGWB)
(Dupuy 1984) and the 36-item short-form (SF-36) (Ware and Sherbourne 1992) have
been applied. In addition, most studies have been cross-sectional and conducted among
adults having the classical intestinal form of coeliac disease (Häuser et al. 2006,
Nachman et al. 2009).
In the majority of studies the quality of life has been decreased in untreated coeliac
disease patients compared either with healthy controls or with the general population
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(Johnston et al. 2004, Viljamaa et al. 2005a, Nachman et al. 2009). In contrast, the
effect of a gluten-free diet on the quality of life is still somewhat unclear. In many
studies coeliac disease patients have achieved normal quality of life while on a gluten-
free diet (Lohiniemi et al. 2000, Johnston et al. 2004, Roos et al. 2006, Nachman et al.
2009), but there are also controversial results showing decreased quality of life despite
treatment (Hallert et al. 1998, Addolorato et al. 2001, Häuser et al. 2006). Usually the
severity of gastrointestinal symptoms has correlated with poorer quality of life (Usai et
al. 2002, Johnston et al. 2004, Nachman 2009), but Mustalahti and associates (2002)
have suggested that also asymptomatic coeliac patients benefit from a gluten-free diet.
Furthermore, in one recent study the screen-detected patients have evinced normal
quality of life while on a long-term gluten-free diet (Viljamaa et al. 2005a), which is
important, since the dietary restrictions could also increase the burden of illness
(Hallert et al. 2002).
Relatively few studies have assessed the quality of life in children and adolescents
with coeliac disease. In a study by group under Kolsteren (2001) paediatric patients
evinced quality of life comparable to that of general population, but recently the same
group observed decreased quality of life when more age- and disease-specific
questionnaires were used (van Doorn et al. 2008). In any case, those coeliac disease
patients who have been diagnosed during childhood seem to achieve in adulthood a
quality of life similar to that in the general population (Wagner et al. 2008).
2.3 Associated conditions and silent coeliac disease
Previously, when the high prevalence was unknown, coeliac disease was taken to be
associated with numerous disorders, in most cases probably simply by coincidence.
Nevertheless, in certain diseases an unusually high prevalence of coeliac disease has
been regularly observed (Table 1). The best-known co-morbidities are type 1 diabetes
mellitus (Visakorpi 1969), autoimmune thyroidal diseases (Kuitunen et al. 1971) and
primary Sjögren´s syndrome (Pittman and Holub 1965). These associations are at least
partly explained by shared genetic risks, but it is possible that other pathogenetic
mechanisms are also involved. It is unclear whether the age at coeliac disease
diagnosis or the dietary treatment has any effects on the development or severity of the
co-morbidities (Ventura et al. 1999, Viljamaa et al. 2005b). Besides autoimmune
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disorders, coeliac disease is overrepresented in some chromosomal abnormalities such
as Down´s and Turner´s syndromes (Bentley 1975, Thatcher et al. 1973). In addition,
coeliac disease is common in patients with selective IgA deficiency, which is clinically
important as these subjects lack IgA-class antibodies (Savilahti et al. 1971, Meini et al.
1996).
Due to augmented serological screening, asymptomatic subjects with positive
coeliac antibodies and a small-bowel mucosal villous atrophy are frequently found
(Ferguson 1993, Vilppula et al. 2008). This is particularly true in patients belonging to
some of the aforementioned risk groups and in the family members of coeliac patients
(Mäki et al. 1991b). Although the natural history of patients having this so-called silent
coeliac disease is poorly understood, evidence suggests that they may carry an
increased risk of osteoporosis and bone fractures (Mazure et al. 1994, Mustalahti et al.
1999). Furthermore, the quality of life and BMD of asymptomatic patients may
improve while on a gluten-free diet (Mustalahti et al. 1999, Mustalahti et al. 2002).
However, in other studies even untreated asymptomatic patients have evinced normal
quality of life (Johnston et al. 2004, Nachman et al. 2009). As screen-detected subjects
also seem to have a low risk of intestinal lymphomas (Mearin et al. 2006) and often
poor dietary compliance (Fabiani et al. 2000), more studies are needed to clarify
whether all asymptomatic coeliac patients should be diagnosed.
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Table 1. The prevalence of coeliac disease in subjects with associated disorders.
Condition and reference Study population Antibody positivity (%)
Coeliac
disease (%)
Type 1 diabetes mellitus
Mäki et al. 1984a 215 children ARA 4.2 2.3
Hansen et al. 2001 106 children AGA 18.3, EmA 9.6, TG2-abs 9,6 10.4
Thyroid disorders
Collin et al. 1994 83 adults AGA 18.1, ARA 4.8, EmA 4.8 4.8
Larizza et al. 2001 90 children EmA 6.6 7.8
Sjögrens´s syndrome
Iltanen et al. 1999a 34 adults AGA 38.2, EmA 8.8 14.7
Szoroday et al. 2004 111 adults EmA and TG2-abs 5.4 4.5
Addisons´s disease
Myhre et al. 2003 76 children and adults AGA 27.6, EmA 6.7, TG2-abs 6.7 7.8
Betterle et al. 2006 5 children, 105 adults TG2-ab 3.7 2.8
Primary biliary cirrhosis
Dickey et al. 1997 57 adults EmA 10.5 7.0
Volta et al. 2002 173 adults EmA 4.0 TG2-abs 4.0 4.0
Autoimmune hepatitis
Volta et al. 1998 181 children and adults AGA 13.8, EmA 4.4 2.8
Villalta et al. 2005 47 adults EmA 6.4 TG2-abs 6.4 6.4
Autoimmune myocarditis
Frustaci et al. 2002 187 adults EmA 4.8, TG2-abs 7.0 4.8
Down´s syndrome
Bonamico et al. 2001a 1110 children, 92 adults AGA 21.5, EmA 5.4 4.6
Wouters et al. 2009 155 children EmA 5.2, TG2-ab 5.2 4.5
Turner´s syndrome
Ivarsson et al. 1999 87 children AGA 14.9, EmA 4.6 4.6
Frost et al. 2009 256 adults EmA 3.2 4.7
Selective IgA deficiency
Meini 1996 65 children AGA 24.6 7.7
IgA nephropathy
Collin et al. 2002 223 children and adults EmA 1.8, TG2-ab 3.6 3.6
ARA, antireticulin antibodies; AGA, antigliadin antibodies; EmA, endomysial antibodies, TG2-abs,
transglutaminase 2 antibodies
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3. SMALL-BOWEL MUCOSAL DAMAGE
The development of intestinal biopsy devices enabled the assessment of coeliac
disease-associated small-bowel mucosal damage in a living person, and it was
discovered that while in a healthy mucosa there are long finger-like villi and short
crypts, characteristic of untreated coeliac disease are villous atrophy and crypt
hyperplasia (Shiner 1957). The most seriously affected areas are usually the duodenum
and the proximal part of jejunum, but the mucosal lesion may be patchy and variable
along the whole length of the small intestine (MacDonald et al. 1964, Scott and
Losowsky 1976). Although considered diagnostic, the villous atrophy is not
pathognomic for coeliac disease, being equally possibly in disorders such as rotavirus
infection, cow's milk allergy, autoimmune enteropathy, giardiasis, tuberculosis,
Crohn´s disease and acquired immunodeficiency syndrome (Kuitunen et al. 1975,
Green and Cellier 2007).
Besides morphological changes, there is an ongoing intestinal inflammation in
untreated coeliac disease and the density of the mucosal cluster-design (CD) 3+
intraepithelial lymphocytes (IELs) is usually increased (Ferguson and Murray 1971,
Kuitunen et al. 1982, Järvinen et al. 2003). Although most of these IELs express ??+ T
cell receptors, a finding more specific to coeliac disease is an abnormally high number
of ??+ IELs (Halstensen et al. 1989, Savilahti et al. 1990, Spencer et al. 1991). In
addition, the density of other inflammatory cells such as mast cells and eosinophils is
often increased in the lamina propria (Savilahti 1972). Another inflammatory marker
of coeliac disease is an abnormal expression of human leukocyte antigen (HLA) DR
antigens (Scott et al. 1981). While in untreated patients gluten-dependent HLA-DR
expression can be seen in the epithelium and in the crypt enterocytes, in non-coeliac
subjects there is no crypt expression and only mild staining of villous enterocytes is
detectable (Scott et al. 1981, Arnaud-Battandier et al. 1986). However, all the
aforementioned inflammatory changes are unspecific and may be present for example
in cow's milk allergy, autoimmune diseases and parasitic infections (Ferguson and
Murray 1971, Kuitunen et al. 1975, Kuitunen et al. 1982, Kakar et al.  2003). Even the
??+ IELs, which are usually considered to be the most specific markers of coeliac
disease, may be increased in other conditions and even without coeliac-type HLA-
DQ2 or DQ8 (Spencer et al. 1991, Iltanen et al. 1999b, Kokkonen et al. 2000).
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It is important to realize that the small-bowel mucosal deterioration in coeliac
disease develops gradually from completely normal mucosa to increased intraepithelial
lymphocytosis, then to hyperplasic crypts, and finally to villous atrophy with crypt
hyperplasia (Figure 1). Depending on the degree of  villous damage the mucosal lesion
can be further classified into partial, subtotal and total villous atrophy (Kuitunen 1982,
Marsh 1992). Furthermore, the villous height/crypt depth ratio (Vh/CrD) can be
calculated, and a ratio <2.0 has usually been used to differentiate the coeliac lesion
from normal mucosal morphology (Kuitunen et al. 1982).
Figure 1. Gradual development of the small-bowel mucosal damage in coeliac disease.
Adapted from Marsh (1992).
4. ANTIBODIES IN COELIAC DISEASE
In the early 1970s it was discovered that the sera of untreated coeliac patients
contained antibodies against food-derived gluten peptides and against certain tissue
structures (Seah et al. 1971, Carswell and Ferguson 1972) and it was soon realized that
these antibodies could be used as non-invasive serological screening tools. Particularly
when the enzyme-linked immunosorbent assay (ELISA) methods became available for
measuring certain coeliac disease-associated antibodies, the diagnostic approach to the
disorder changed completely (O´Farrelly et al. 1983, Sulkanen et al. 1998a).
MARSH 0 MARSH I MARSH II MARSH III
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4.1 Serum antigliadin antibodies
Serum antigliadin antibodies (AGA) were previously widely used in case-finding in
coeliac disease (Hill et al. 2005). Unfortunately, AGA may be present in many
disorders other than coeliac disease (Unsworth et al. 1983, Mäki 1995), and studies
have shown heterogeneous sensitivities and specificities from only about 30% up to
100% (McMillan et al. 1991, Mäki et al. 1991, Vogelsand et al. 1995, Sulkanen et al.
1998a). Furthermore, by reason of the variable accuracy of the IgA- and IgG-class
AGA among coeliac patients and the possibility of selective IgA deficiency, the
antibodies are usually measured together (Savilahti et al. 1983). In view of this
diversity of results, AGA are not currently recommended as the primary serological
method for suspected coeliac disease, although they may still be valuable in children
below two years of age (Hill et al. 2005, Maglio et al. 2010).
Interestingly, a necessary step in the pathogenesis of coeliac disease is a
deamidation of gliadin peptides to form more specific epitopes to intestinal T-cells
(Molberg 1998). The immune system may also form antibodies also against these
deamidated gliadin peptides (Aleanzi et al. 2001), and several recent studies have
shown that these antibodies have significantly higher diagnostic accuracy than the
conventional AGA (Scwertz et al. 2004, Kaukinen et al. 2007a). Besides being
accurate, antibodies to deamidated gliadin peptides might be the first serological
markers of untreated coeliac disease, indicating that they could offer a promising
method for the early detection of coeliac patients (Simell et al 2007, Liu et al. 2007).
4.2 Serum reticulin, endomysial and TG2 antibodies
The first autoantibodies in coeliac disease were discovered by Seah and associates
(1971), who detected specific a antibody reaction against reticulin fibres in connective
tissue. These R1-type antireticulin antibodies (ARA) could be measured in both IgA
and IgG class by using indirect immonoflurescence on rodent tissues, but the IgA-class
antibodies were later shown to be superior for untreated coeliac disease (Mäki et al.
1984b). The sensitivity of ARA has sometimes been rather low (Volta et al. 1991), but
in most studies the specificity has been more than 90% and thus substantially higher
than that of AGA (Seah et al. 1971, Mäki et al. 1984b, Hällström 1989, Kolho and
Savilahti 1997). Due to this superior specificity, ARA were widely used even in the
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late 1990s, but in 1983 a new autoantibody targeted against monkey oesophageal
endomysium was discovered (Chorzelski et al. 1983). These endomysial antibodies
(EmA) were shown to have sensitivity and specificity for coeliac disease similar to or
even better than ARA (Table 2), but they became widely accepted after Ladinser  and
collegues (1994) observed that human umbilical cord could be used as a substitute for
monkey oesophagus.
Despite the high accuracy of ARA and EmA it remained unclear which were the
antigens they recognized until Dieterich and associates (1997) discovered that the
autoantigen in monkey oesophagus smooth muscle cell endomysium was TG2. TG2 is
ubiquitous enzyme catalyzing different transamidating and deamidating reactions, and
also having a major role in the pathogenesis of coeliac disease (Molberg et al. 2000).
Antibodies specific to TG2 (TG2-abs) could be measured and evinced high accuracy
for coeliac disease comparable to EmA (Dieterich et al. 1998, Sulkanen et al. 1998a).
A few years later Korponay-Szabo and associates (2000, 2003a) showed that ARA,
EmA and TG2-abs are in fact structurally almost identical and that ARA were also
targeted against TG2. As the TG2-abs can be measured by a practical ELISA method
(Sulkanen et al. 1998a) they are often used, with human recombinant TG2 as an
antigen, as the primary screening method for coeliac disease in clinical practice.
Although the introduction of EmA and TG2-abs brought a great advance in non-
invasive case-finding in coeliac disease, they have certain limitations. When applied in
a validated laboratory EmA shows excellent specificity, but the immunofluerescence
method is laborious, time-consuming and somewhat subjective. In addition, the good
accuracies of EmA and TG2-abs have been shown mainly in well-controlled research
conditions and might be poorer in clinical settings (Rostami et al. 1999). Particularly
TG2-abs have yielded relatively heterogeneous results depending on the laboratory or
methods used (Hopper et al. 2007), and both antibodies are less reliable in children
below two years of age (Mankai et al. 2005). Furthermore, in the case of selective IgA
deficiency, the antibodies should be measured in IgG class (Sulkanen et al. 1998b,
Korponay-Szabo et al. 2003b).
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Table 2. Studies of the sensitivities and specificities of serum IgA-class endomysial (EmA) and
tissue transglutaminase 2 (TG2-ab) antibodies for untreated coeliac disease
EmA TG2-ab
Reference Patients Controls
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
Hällström et
al. 1989
14 children,
32 adults
24 children,
145 adults
93.5 99.3 ND ND
Sulkanen et
al. 1998a
136 children
and adults
207 children
and adults
92.6 99.5 94.9 93.7
Biagi et al.
1999
39 adults 61 adults 100 100 94.8 90.1
Bonamico et
al. 2001b
62 children 56 children 95.2 98.2 90.3 100
Bürgin-Wolff
et al. 2002
208 children
and adults
157 children
and adults
96.6 100 96.1 99.4
Tesei et al.
2003
250 adults 176 adults 85.6 100 90.0 94.9
Mankai et al.
2005
97 children,
46 adults
74 children
and adults
95.8 100 86.0 95.9
Collin et al.
2005a
126 children
and adults
106 children
and adults
88.9 98.1 93.6 99.1
Volta et al.
2008
128 children
and adults
134 adults 93.7 100 96.8 91.0
Raivio et al.
2008
139 children
and adults
103 children
and adults
99.3 100 98.6 99.0
Hopper et al.
2008
77 adults 1923 adults 87.0 98.0 90.9 90.9
ND, no data
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4.3 Small-bowel mucosal autoantibody deposits
A few decades ago it was observed that the small-bowel mucosa of coeliac disease
patients contained specific deposits of immunoglobulin A (IgA deposits) (Shiner and
Ballard 1972, Kárpáti et al. 1988), which were subsequently shown to be targeted
against extracellular TG2 (Korponay-Szabo et al. 2004). These deposits can be found
in practically all patients having classical villous atrophy coeliac disease (Koskinen et
al. 2008). Since the TG2-abs are also produced locally in the mucosa (Marzari et al.
2001), it seems that after formation the autoantibodies bind primarily to the
extracellular TG2 and as a spilling effect enter into circulation (Korponay-Szabo et al.
2004). In fact, the antibodies can be detected in the mucosa even while not present in
serum (Salmi et al. 2006a). This is important in that the sensitivity of EmA or TG2-abs
is not always optimal and sometimes coeliac disease patients are missed due to false
seronegativity. Interestingly, IgA deposits can be found even before villous atrophy
develops (Kaukinen et al. 2005, Salmi et al. 2006b), and since the deposits also evince
high specificity (Kaukinen et al. 2005, Tosco et al. 2008, Koskinen et al. 2008), they
could be utilized in cases with strong clinical suspicion of coeliac disease but normal
mucosal structure and negative autoantibodies. Nevertheless, the sensitivity of the
deposits may be lower in children below two years of age (Maglio et al. 2010), and the
need for special methods and frozen samples limits their utility in clinical settings.
4.4 Rapid tests
The coeliac autoantibodies can be measured only in specialized laboratories, which is
expensive, time-consuming and even impossible in many developing countries. These
problems have led to the development of new on-site tests in which high accuracy is
combined with very short measurement time (Sorell et al. 2002). Particularly
interesting is a new self-TG2-based point-of-care test, as it requires only a fingertip
blood sample and evinces high accuracy for coeliac disease similar to the conventional
EmA and TG2-abs (Korponay-Szabo et al. 2005, Raivio et al. 2006).
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5. PATHOGENETIC ASPECTS OF COELIAC DISEASE
The development of coeliac disease is an end result of a complex interaction between
genes, environmental factors and the immunological system of the small intestine. As
in many complex diseases, the contribution of different predisposing and protecting
factors in coeliac disease is difficult to assess, but rapid developments in the fields of
genetics and immunology in the last few decades have enormously increased our
understanding of the pathogenesis.
5.1 Genetics
The heritability of coeliac disease was shown by MacDonald and colleagues (1965)
more than 40 years ago. The prevalence of the disorder among first-degree relatives is
approximately 10-20% (Mäki 1991b, Greco 2002) and the high concordance rate of up
to 90% between monozygotic twins further confirms its genetic nature (Hervonen et al.
2000, Greco et al. 2002). The association of coeliac disease with certain HLA
molecules in chromosome region 6p21.3 was discovered in the early 1970s (Stokes et
al. 1972) and was later defined to comprise specific alleles encoding HLA DQ2 and
DQ8 molecules (Sollid et al. 1989). Lundin and associates (1993, 1994) demonstrated
the causal connection of these haplotypes by showing that gluten activates HLA DQ2-
and DQ8-restricted T-cells in the small intestine of coeliac disease patients. The
observed correlation between the number of predisposing HLA-DQ alleles and the risk
of coeliac disease gives further evidence for the role of these haplotypes in the
pathogenesis (Vader et al. 2003).
More than 90% of coeliac patients have the HLA DQ2 (DQA1*0501/DQB1*0201)
and almost all the rest the DQ8 (DQA1*0301/ DQB1*0302) haplotype (Sollid and
Thorsby 1993, Karell et al. 2003). However, although the combined prevalence of
HLA DQ2 and DQ8 in the population is approximately 30%, most individuals will
never develop coeliac disease. Furthermore, the concordance of the disorder among
HLA compatible siblings is only about 30% (Mearin et al. 1983). It has since been
estimated that the HLA region contributes to less than half of the genetic risk for
coeliac disease and numerous studies have sought to uncover potential non-HLA risk
genes (van Heel et al. 2007, Hunt et al. 2008). Thus far results have been somewhat
inconsistent and have varied between different populations, but an association with
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certain specific chromosome regions, particularly 5q31-33, 2q33 and 19p13, has
frequently been reported (Liu et al. 2002, Holopainen et al. 2004, Monsuur et al.
2005). These findings are supported by the biologically relevant candidate genes
detected within these chromosome areas, for example CTLA-4, ICOS and MYO9B
(Holopainen et al. 2004, Monsuur et al. 2005). In addition, three large-scale genome-
wide association studies in coeliac disease have recently been conducted and as a
result several new potential non-HLA loci have been identified. These new genetic risk
regions are particularly interesting since many of them have been linked to type 1
diabetes and also to some other autoimmune diseases (van Heel et al. 2007, Hunt et al.
2008, Dubois et al. 2010). Nevertheless, it seems that the currently known non-HLA
regions explain only a tiny fraction of the genetic background of coeliac disease
(Dubois et al. 2010).
5.2 Environmental factors
5.2.1 Dietary factors
Dietary prolamins in wheat, barley and rye are the principal environmental trigger for
coeliac disease. Wheat prolamins normally function as a storage protein in the grain
and are composed of two different protein fractions, namely gliadins and glutenins. In
addition, the barley and rye prolamins hordein and secalin contain structurally similar
proteins and can also cause coeliac disease (Anand et al. 1978). The three-dimensional
structure of gliadin can enhance the baking properties of dough and breeding has thus
favoured cereals with a high gluten concentration, simultaneously increasing the risk
of coeliac disease at population level (Guandalini 2008).
Besides being necessary triggering factor, the age at gluten introduction and its
amount in the diet in infancy may influence the risk of coeliac disease, as
demonstrated by a remarkable increase in the coeliac disease incidence in Sweden
after new feeding recommendations in the 1980s (Ascher et al. 1993). It was later
shown that children who developed coeliac disease consumed higher amounts of
gluten than their healthy counterparts (Ivarsson et al. 2002). Although in the study in
question the age at gluten introduction did not affect to coeliac disease risk, it has since
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been suggested that the optimal age to introduce gluten would be between four to six
months (Norris et al. 2005).
Whether breastfeeding or its duration affects to risk of coeliac disease is difficult to
evaluate by reason of the obvious connection with gluten consumption.
Epidemiological evidence suggests that breastfeeding might offer protection
(Andersen and DiSant´Agnese 1953, Ivarsson et al. 2002), but there are results to the
contrary and it is possible that prolonged breastfeeding only delays the onset of clinical
symptoms (Akonbeng et al. 2006).
5.2.2 Other environmental factors
Certain microbes such as adeno- and rotaviruses have been suggested to increase the
risk of coeliac disease (Kagnoff et al. 1987, Stene et al. 2006, Zanoni et al. 2006) and
the seasonal pattern observed in the incidence supports the role of infections (Ivarsson
et al. 2003). On the other hand, recurrent infections may have a protective role. The
prevalence of coeliac disease and many other autoimmune diseases has increased
rapidly in the past few decades (Bach et al. 2002, Lohi et al. 2007), suggesting that
decreased exposure to microbiological agents in childhood predisposes the immune
system to react against self-antigens (Strachan 1989, Plot et al. 2009). This theory was
recently supported by Kondrashova and associates (2008), who observed a six-fold
lower prevalence of coeliac disease in Russian Karelia than in Finland. Since people in
these two areas have a similar genetic background and daily gluten consumption, the
authors hypothesized that the disparity was caused by the lower standard of living and
higher exposure to infections in Russia.
Certain other aspects of lifestyle and environment such as cigarette smoking and
socioeconomic status may modulate the risk of developing coeliac disease (Austin et
al. 2002, Ivarsson 2005). However, the evidence is mainly epidemiological and more
studies are needed to assess the true causal implication of these environmental factors.
5.3 Pathogenetic mechanisms
The toxicity of wheat in coeliac disease is connected mainly to certain specific gliadin
peptides (Sollid 2000). Characteristic of gliadin is the high concentration of the amino
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acids proline and glutamine, which enable immunogenic polypeptides to survive
intestinal degradation (Frazer et al. 1959, Shan et al. 2002). Before immunological
reactions can be initiated the gliadin peptides must penetrate the intestinal epithelium,
which under normal conditions is highly resistant. However, in untreated coeliac
disease an increased permeability can be observed, although the mechanisms behind
this are still somewhat obscure (Madara et al. 1980, Fasano et al. 2000). It has been
recently observed that in coeliac disease gluten induces a release of a certain
prehaptoglobulin 2 precursor called zonulin (Fasano et al. 2000, Tripathi et al. 2009).
Zonulin is a regulator of the epithelial tight junctions and after the binding of gliadin to
the chemokine receptor CXCR3 zonulin may increase the paracellular permeability
(Lammers et al. 2008). In addition, the gliadin peptides could pass the epithelium with
the help of dendritic cells (Rescigno et al. 2001) or by a transcellular pathway through
enterocytes (Zimmer et al. 1995, Matysiak-Budnik et al. 2003, Schumann et al. 2008).
Once the immunogenic peptides reach the submucosal layer, they can activate
adaptive immunological reactions. The process starts when gluten peptides are
presented to specific CD4+ T cells by the HLA DQ2 or DQ8 molecules of antigen-
presenting cells (Lundin et al. 1993 and 1994). Intact peptides lack negatively charged
amino acid residues and thus have a low affinity for HLA DQ molecules (van de Wal
et al. 1996). However, the high concentration of glutamine in gluten makes it an
excellent substrate to TG2, which specifically deamidates the glutamine residues to
negatively charged glutamate, thus enabling the formation of HLA DQ-gliadin
complexes and subsequent CD4+ T cell responses (Molberg et al. 1998, van de Wal et
al. 1998). The activation of  T cells leads to the production of cytokine interferon ?
(Nilsen et al. 1998) which, alongside other inflammatory mediators such as tumour
necrosis factor ?, can induce crypt hyperplasia and exert direct cytotoxicity on
epithelial cells (Bajaj-Elliot et al. 1998, Deem et al. 1991). Furthermore, the increased
release of different metalloproteinases leads to deterioration of the small-bowel
mucosal structure (Daum et al. 1999).
The important role of the innate immune system in the pathogenesis of coeliac
disease has recently been recognized. Studies have shown that gluten triggers
immunological responses independently of adaptive T cell reactions and that
interleukin 15 (IL-15) is the most important mediator of these responses (Jabri et al.
2000, Maiuri et al. 2003). In the small-bowel mucosa innate reactions can increase the
density of IELs, and subsequently cause intestinal epithelial cell lysis and mucosal
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damage through the NKG2D-MIC pathway (Hüe et al. 2004). These observations
suggest that both innate and the adaptive immunology are required for the
development of coeliac disease, this perhaps partly explaining why only a minority of
those who have the HLA DQ2 or DQ8 genotype will eventually suffer from the
disorder (Maiuri et al. 2003).
The presence of TG2-abs is a hallmark of coeliac disease (Dietrich et al. 2007), but
their significance in the pathogenesis has remained obscure. These antibodies are
formed in the intestinal mucosa (Marzari et al. 2001), but in contrast to gliadin-specific
T cells (Molberg et al. 1997), intestinal TG2-specific T cells have not been detected
and it is still unclear how the TG2-abs are produced (Lindfors et al. 2009). As a
possible explanation, a so-called hapten-carrier mechanism has been proposed (Mäki
1994, Sollid et al. 1997). In this model the gluten peptides and TG2 are presented
together to the gluten-specific CD4+ T cells, which then help B cells to produce TG2-
specific antibodies. In addition, some forms of molecular mimicry may participate in
this antibody production (Kagnoff et al. 1987, Zanoni et al. 2006, Korponay-Szabo et
al. 2008).
Once formed, the TG2 antibodies may evince biological activity. Halttunen and
Mäki (1999) have shown that IgA from untreated coeliac patients inhibits the
differentiation of intestinal epithelial cells in vitro. Furthermore, the antibodies can
reduce mesenchymal cell motility and increase matrix degeneration (Barone et al.
2007), disturb growth of the villous structures by inhibiting angiogenesis (Myrsky et
al. 2008), increase epithelial permeability (Zanoni et al. 2006) and modulate the
transamidating activity of TG2 (Esposito et al. 2002). After entering the circulation the
antibodies might also contribute to the extraintestinal manifestations by depositing in
different tissues (Korponay-Szabo et al. 2004). Such autoantibody deposits have been
detected around blood vessels of the liver in subjects with severe liver disease
(Korponay-Szabó et al. 2004) and in the brain of gluten ataxia patients (Hadjivassiliou
et al. 2008a). Furthermore, in a mouse model antibodies from an untreated coeliac
patient were found deposited around the cerebellar blood vessels and caused ataxia-
like symptoms (Boscolo et al. 2007). Interestingly, patients with dermatitis
herpetiformis have autoantibodies targeted against TG3 (Sardy et al. 2003) and those
with gluten ataxia against TG6 (Hadjivassiliou et al. 2008b), indicating that the
extraintestinal manifestations could be determined by the type of TG against which the
antibodies are targeted (Lindfors et al. 2009).
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Figure 2. Pathogenetic mechanisms in coeliac disease. Incompletely digested gluten
peptides pass the intestinal epithelium either paracellularly after increased zonulin
release or through the enterocytes and are deamidated by transglutaminase 2 (TG2).
The deamidated peptides are presented to T-cells by the antigen-presenting cells
(APC), and subsequently produce proinflammatory cytokines such as interferon g
(INF-g) and tumour necrosis factor a (TNF-a), which are detrimental to mucosal
integrity. Other gluten peptides can be directly cytotoxic and activate innate immunity
via interleukin 15 (IL-15). The gluten-stimulated T-cells also help B-cells to produce
TG2-targeted autoantibodies, which may increase epithelial permeability, disturb
angiogenesis and modulate the deamidating activity of TG2. In addition, the
circulatory autoantibodies may participate in the extraintestinal manifestations of
coeliac disease.
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6. EPIDEMIOLOGY OF COELIAC DISEASE
Previously, when the extraintestinal and silent forms were largely unknown, coeliac
disease was considered to be mainly a rare disease of childhood (Davidson and
Fountain 1950). Even in the 1980s the prevalence was estimated to be about 0.1% and
the incidence was actually thought to be decreasing (Stevens et al. 1987). It was,
however, soon realized that the clinical presentation had become milder and had
shifted to older age groups (Logan et al. 1983, Mäki et al. 1988a). Recent population-
based screening studies have shown the prevalence of coeliac disease to be
approximately 1% in both children (Fasano et al. 2003, Hoffenberg et al. 2003, Mäki
et al. 2003, Korponay-Szabo et al. 2007) and adults (Fasano et al. 2003, West et al.
2003). The prevalence also appears to increase by age, as shown by the significantly
higher seropositivity (up to 2.7%) in the elderly population (Vilppula et al. 2009). It is
of note that not only the number of cases found but also the true prevalence of coeliac
disease has increased. In a study by a group under Lohi (2007), coeliac seropositivity
had almost doubled from one to two percent in the Finnish population during the past
two decades, and a similar trend was recently observed in the United States (Rubio-
Tapia et al. 2009). It is possible that changes in our microbiological environment are
behind this phenomenon (Section 5.2.2).
There are substantial differences in the geographical distribution of coeliac disease.
For example, the disorder is very rare in Asian countries like China and Japan,
whereas so far the highest seroprevalence, 5.6%, has been detected among Saharawi
children in Northern Africa (Catassi et al. 1999). These disparities are probably related
to variations in genetic predisposition and the amount of gluten in the daily diet.  In
addition, an extraordinarily high prevalence of up to 3% has been revealed in children
born during the Swedish epidemic of coeliac disease (Myléus et al. 2009; see Section
5.2 ).
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7. TREATMENT OF COELIAC DISEASE
7.1 Dietary treatment
Strict avoidance of wheat, barley and rye is the cornerstone of treatment in all forms of
coeliac disease. The safety of oats has been questioned since it is taxonomically related
to the prohibited cereals, but prospective studies have shown that oats is safe for the
majority of patients (Janatuinen et al. 1995, Högberg et al. 2004, Holm et al. 2006).
Nevertheless, in some case reports oats has caused small-bowel mucosal damage and
thus might not be suitable for all coeliac patients (Lundin et al. 2003). Another
question has been whether the cereals in question should be naturally gluten-free, but
several studies have shown that industrially purified wheat starch products which in
theory might contain trace amounts of gluten are also safe for coeliac patients
(Kaukinen et al. 1999, Lohiniemi et al. 2000, Peräaho et al. 2003).
The initiation of a gluten-free diet usually alleviates gastrointestinal symptoms
within days and the small-bowel mucosal deterioration also begins to improve rapidly,
although the complete normalization of the mucosa may take several years (Yardley et
al. 1962, Grefte et al. 1988). In addition, most of the malabsorptive symptoms
disappear on a gluten-free diet even without supplementary medication (Annibale et al.
2001). Dietary treatment is also beneficial in the case of extraintestinal manifestations
and complications of coeliac disease. It may improve ataxia (Pellechia et al. 1995,
Hadjivassilou et al. 2008) and peripheral neuropathy (Kaplan et al. 1988), reduce
epileptic seizures (Hernández et al. 1998), alleviate depression (Pynnönen et al. 2005)
and improve the quality of life (Hallert 1998). In addition, gynaecological and
obstetric problems (Smecuol et al. 1996), arthritis (Mäki et al. 1988b, Collin et al.
1992) and liver dysfunction (Hagander et al. 1977, Bardella et al. 1995, Kaukinen et al.
2002) may disappear during dietary treatment. A gluten-free diet also seems to reduce
both the risk of malignant diseases (Holmes et al. 1989, Collin et al. 1996a) and
mortality in coeliac patients (Corrao et al. 2001). Decreased BMD usually increases
while on diet (Mora et al. 1993, Valdimarsson et al. 1994, Mustalahti 1999, Tau et al.
2006), but to ensure normal bone maturation the treatment should be started as early as
possible (Mora et al. 1999, Tau et al. 2006). Early-initiated treatment also enables
successful catch-up growth in children with coeliac disease (Barr et al. 1966).
Although a gluten-free diet is the treatment of choice in dermatitis herpetiformis (Fry
38
et al. 1973), sufferers seem to be particularly sensitive to trace amounts of gluten, and
additive anti-inflammatory dapsone medication is often required for the first few years
following the diagnosis (Kruizinga and Hamminga 1953, Reunala 2001).
It must be emphasized that despite all the aforementioned benefits, a life-long
gluten-free diet is expensive and difficult to maintain, and may involve social
restrictions (Hallert et al. 2002a, Lee et al. 2007). In addition, the diet may induce an
undesirable intake of fat and sugar, leading to detrimental weight gain (Mariani et al.
1998, Dickey and Kearney 2006), and there is also evidence of poor vitamin status
after a long-term gluten-free diet (Hallert et al. 2002b). Furthermore, long-term
compliance with the gluten-free diet may be rather poor (Fabiani et al. 2000, Högberg
et al. 2003, Whitaker et al. 2009), suggesting that there is a need for other treatment
options.
7.2 New treatment options
Several alternative means of treating coeliac disease are emerging and some are
already on clinical trial (Sollid and Khosla 2005). Unfortunately, a well-defined animal
model of coeliac disease is lacking and thus potential new approaches can be tested
only in cell and tissue models before human trials are launched.
Eradication of the toxic gliadin sequences from cereals by genetic engineering
could prevent coeliac disease at population level (Vader et al. 2003), but at present
technical and ethical problems restrict genetic modification of food products. Another
preventive option could be degradation of the immunogenic polypeptides by means of
specific endoproteolytic enzymes, either during baking or while in the stomach
(Hausch et al. 2002, Piper et al. 2004, Stenman et al. 2009). Many of these enzymes
have the benefit of being already used in the food industry and thus possessing a well-
defined safety profile (Sollid and Khosla 2005). Finally, the penetration of the toxic
peptides to the intestinal epithelium could be inhibited by using specific zonulin
antagonists (Paterson et al. 2007).
Even after the toxic gliadin has entered the body the immunological reaction could
be blocked at several points. Experimental evidence suggests that inhibition of TG2
may reduce gluten-induced T cell activation (Molberg et al. 2001, Maiuri et al. 2005).
In addition, a number of other inhibitory agents such as HLA-DQ2 molecule blockers
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and IL-10 or IL-15 agonists have been proposed (Sollid and Khosla 2005). Finally, the
novel idea has been introduced of using peptide-based immunotherapy to tolerize
patients to the toxic gliadin epitopes (Camarca et al. 2009).
7.3 Refractory coeliac disease
Occasionally coeliac patients fail to achieve a clinical and histological response despite
treatment with a gluten-free diet. In these cases the treatment should be revised by a
trained dietitian, since some inadvertent gluten intake may have remained. If no
dietary failures are observed, the original diagnosis should be re-assessed. The small-
bowel mucosal villous atrophy could also be caused by disorders other than coeliac
disease (Chapter 3), but the presence of coeliac autoantibodies in the serum or in the
small-bowel mucosa and the pertinent HLA type are strongly suggestive of correct
diagnosis. If all other reasons for the treatment failure are excluded, the condition is
defined as refractory coeliac disease (Trier et al. 1978).
Depending on the immunophenotype of the IELs, refractory coeliac disease can be
divided into subtypes 1 and 2. Both subtypes are virtually non-existent in children,
indicating that a long-term exposure to gluten is needed for their development (Al-
Toma et al. 2007a). In addition, homozygosity for the HLA-DQ2 genotype or the
presence of a specific MYO9B gene region are significant risk factors (Al-Toma et al.
2006a, Wolters et al. 2007). Patients with either type 1 or 2 refractory coeliac disease
usually suffer from typical coeliac-type gastrointestinal symptoms and evince
persistent small-bowel mucosal villous atrophy (Al-Toma et al. 2007a). However,
while type 1 is a fairly benign disorder, in type 2 disease the immunophenotype of
IELs is abnormal, showing clonal T cell receptor gene rearrangements and loss of T
cell antigens, and it is a severe disease with high mortality (Cellier et al. 1998). In type
1 disease prednisolone and azatioprine are often effective (Goerres et al. 2003). In
contrast, although intensive chemotherapy and immunomodulators may be helpful, the
prognosis in type 2 disease is usually rather poor (Al-Toma et al. 2006b, Turner at al.
2005). If all other treatments have failed, autologous stem cell transplantation might be
considered (Al-Toma et al. 2007b).
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8. DIAGNOSTIC CRITERIA AND NATURAL HISTORY OF
COELIAC DISEASE
8.1 Current diagnostic criteria
The first diagnostic criteria for coeliac disease were established by the European
Society for Paediatric Gastroenterology and Nutrition (ESPGAN) in 1970 (Meeuvisse
1970). In these criteria the diagnosis was based on three separate small-bowel biopsies
showing an initial mucosal villous atrophy, then histological remission while on a
gluten-free diet and finally mucosal relapse within two years on a gluten challenge.
These criteria were revised in 1990 and it was stated that in symptomatic children at
least partial small-bowel mucosal villous atrophy, together with a good clinical
response to treatment, is sufficient for the diagnosis (Walker-Smith et al. 1990).
However, in asymptomatic patients histological recovery should be demonstrated, and
in unclear cases an additional gluten challenge is still recommended. The presence of
coeliac antibodies is not necessary but gives further evidence for the diagnosis. These
criteria are still widely used in all age groups, but in adults a second small-bowel
biopsy is usually recommended regardless of the initial presentation (United European
Gastroenterology 2001, Hill et al. 2005). The diagnosis of dermatitis herpetiformis is
based on the demonstration of granular IgA deposits in the dermal papillae of the skin
close to the active lesion (van der Meer 1969).
8.2 Early developing coeliac disease
There is mounting evidence to indicate that small-bowel mucosal villous atrophy with
crypt hyperplasia represents only the end-point in the wide clinical spectrum of coeliac
disease. The intestinal damage evolves gradually from completely normal mucosa to
overt villous atrophy (Marsh 1992) and this deterioration may take years or even
decades to develop despite continuous gluten consumption (Egan-Mitchell et al. 1981,
Mäki et al. 1990, Collin et al. 1993, Lähdeaho et al. 2005). Furthermore, the severity
of the clinical symptoms and the degree of mucosal villous atrophy do not necessary
correlate (Kaukinen et al. 2001, Esteve et al. 2006, Murray et al. 2008). The well-
defined concept of latent coeliac disease describes patients who have initially had
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normal small-bowel mucosal structure but who have later developed villous atrophy
while on a gluten-containing diet (Ferguson et al. 1993). A number of studies of latent
coeliac disease are shown in Table 3, and it can be seen that in many cases patients
have evinced clinical symptoms and signs of small-bowel mucosal inflammation while
the villous structure was still normal. In consequence of the persisting symptoms and
fear of possible complications, patients are often willing to start treatment despite the
lack of a definite histological diagnosis. Table 4 shows studies in which an
experimental gluten-free diet has been initiated without the demonstration of villous
atrophy, and it can be seen that in many cases there has been beneficial serological and
clinical response to early treatment, and also that the early mucosal changes have been
alleviated.
Such results suggest that the current diagnostic criteria requiring small-bowel
mucosal villous atrophy and crypt hyperplasia are insufficient to cover all the variable
presentations of the coeliac-type disorders. Interestingly, there is already a well-
defined model for coeliac disease without villous atrophy. Patients with dermatitis
herpetiformis usually show signs of small-bowel mucosal damage indistinguishable
from that in intestinal disease (Marks et al. 1966), and although in almost one third of
cases there are only non-atrophic inflammatory changes in the mucosa, treatment with
a gluten-free diet is still indicated (Savilahti et al. 1992, Reunala 2001). Similarly,
patients with gluten ataxia may have positive serum coeliac antibodies, the appropriate
HLA-type and even TG2-specific IgA deposits in the intestinal mucosa, but small-
bowel villous atrophy is present in only a minority of these gluten-sensitive patients
(Hadjivassiliou et al. 2008a). Nevertheless, intolerance to gluten-containing cereals
and increased IELs are too unspecific for a definitive diagnosis of coeliac disease
(Kaukinen et al. 2000, Kuitunen et al. 1982, Järvinen et al. 2003, Salmi et al. 2006)
and more reliable markers for an early developing disorder are needed.
The presence of either the HLA DQ2 or DQ8 genotype is practically a requirement
for coeliac disease, but is an unspecific finding and can be used only as an exclusive
method before further investigations (Karell et al. 2003, Esteve et al. 2006). In
contrast, an increased mucosal ??+ IEL count is a much more specific marker, and
may also be detectable before villous atrophy develops (Mäki et al. 1991a, Kaukinen et
al. 1998, Iltanen et al. 1999c, Järvinen et al. 2004). However, even these cells may be
elevated in other conditions (Spencer et al. 1991, Iltanen et al. 1999b, Järvinen et al.
2003), and the need for frozen sample and special methods limits their usefulness in
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clinical practice. As an improvement to the classical morphometric methods requiring
only paraffin sections, determination of villous tip IELs has been shown to evince
specificity similar to that of ??+ IELs, but further studies are needed to clarify the role
of this method in diagnosis (Järvinen et al. 2004, Salmi et al. 2010). As a conclusion, it
is obvious that all the aforementioned methods are insufficient for a definitive
diagnosis of early-developing coeliac disease.
At present EmA and TG2-abs are frequently used as a first-line screening method in
cases of coeliac disease suspicion before any histological investigation. As a result of
intensified serological screening, subjects with positive antibodies but normal small-
bowel mucosal villi are increasingly found (Mäki et al. 2003, Fasano et al. 2003,
Ludvigsson et al. 2009). Although these subjects are usually considered to represent
false positivity, it can be seen from the Table 3 that in many cases positive antibodies
have actually predicted forthcoming villous atrophy. In fact, the appearance of these
antibodies would appear to constitute very early phenomenon in the pathogenesis of
coeliac disease, to be followed only later followed by the typical histological changes
and clinical presentation (Korponay-Szabo et al. 2004, Simell et al. 2007 and 2010).
Since particularly EmA and TG2-abs also have high specificity (Table 2), their
presence before villous atrophy develops could offer a promising basis for early
identification of the disorder. Nevertheless, thus far no controlled follow-up study has
been carried out in subjects with positive coeliac antibodies but normal villous
structure, and there is no consensus as to either their diagnosis or treatment with a
gluten-free diet (Hill et al. 2005).
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Table 3. Studies involving patients who had normal small-bowel mucosal stucture at baseline but who later developed villous atrophy and crypt hyperplasia
while on a gluten-containing diet.
Reference
Total cases
followed
Baseline symptoms in those who
developed coeliac disease
Serum antibodies
at baseline
Mucosal findings at
baseline Final diagnosis n (%)
Follow-up
time median
(range)
Weinstein 1974 2 adults asymptomatic ND structurally normal 2 (100) 4 and 8
months
Egan-Mitchell
et al. 1981
1 child abdominal, poor growth ND structurally normal 1 (100) 1 year
Mäki et al. 1990 3 children and
1 adult
2 malabsorption, 1 extraintestinal,
1 asymptomatic
1/4 ARA and
EmA
structurally normal,
1 had incresed IELs
4 (100) 5.7 (2.6-9)
years
Mäki et al. 1991a 1 adult asymptomatic ARA increased CD3+ and
??+ IELs
1 (100) 2 years
Mäki et al. 1991b 7 children and
adults
ND 7/7 ARA or EmA structurally normal 3 (43) (3 had ARA at
baseline)
3 years in all
Collin et al. 1993 25 adults ND 6/25 ARA
22/25 AGA
structurally normal 7 (28) (6 had ARA at
baseline)
3 (1-5) years
Troncone 1995 ND, children 3 abdominal, 4 poor growth,
2 extraintestinal, 3 asymptomatic
ND structurally normal 14 (ND) (2 had EmA
at baseline)
1.8 (1-10)
years
Corazza et al. 1996 ND, adults 1 abdominal, 1 malabsorption,
1 asymptomatic
ND structurally normal 3 (ND) (2 had EmA at
baseline)
3 (0.2-13)
years
Kaukinen et al. 1998 12 adults 3 abdominal, 1 weight loss,
1 anaemia
5/12 ARA,
8/12 AGA
increased  CD3+,
??+ and ??+ IELs
5 (42) (2 had ARA at
baseline )
ND (0.3-1.5)
years
Iltanen  et al. 1999b 18 children ND 18/18 ARA increased  CD3+,
??+ and ??+ IELs
4 (22) (all had ARA at
baseline)
ND (1.5-4.5)
years
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Iltanen et al. 1999c ND, children 5 abdominal, 3 poor growth,
1 asymptomatic
ND Marsh 0-I 9 (ND) (8 had EmA at
baseline)
ND (0.8-4.5)
years
Murray et al. 2001 14 adults 4 anaemia 3/9 EmA,
3/9 AGA
Marsh I-II 4 (29) (3 had EmA at
baseline)
4 (3-5) years
Sbarbati et al. 2003 6 children and
1 adult
1 abdominal, 1 anaemia, 2 poor
growth, 3 asymptomatic
7/7 EmA,
5/7 AGA
structurally normal 2 (40) (2 had EmA at
baseline)
1 year in both
Järvinen et al. 2004 ND, adults 12 abdominal, 1 anaemia,
4 asymptomatic
ND Marsh 0-I 17 (ND) (12 had EmA
at baseline)
ND
Lähdeaho et al. 2005 148 children ND 3/148 EmA,
5/148 AGA
structurally normal 6 (4) (3 had EmA at
baseline)
10 (0.5-21)
years
Dickey et al. 2005 8 adults symptomatic 8/8 EmA Marsh 0-I 6 (75) (all had EmA at
baseline)
1.5 (1-6) years
Salmi et al. 2006b 47 adults 8 abdominal, 5 extraintestinal,
4 asymptomatic
ND Marsh 0-I
14/15 IgA deposits
17 (36) (13 had ARA
or EmA at baseline)
2.2 (0.2-7.4)
years
Grodzinsky et al.
2008
19 children ND 19/19 EmA structurally normal 11 (58) (all had EmA
at baseline)
ND
Mohamed et al. 2008 14 adults 3 abdominal, 1 anaemia, 1
extraintestinal, 1 weight loss
14/14 EmA
5/14 TG2-abs
increased CD2+, 3+,
7+, 8+ and 69+ IELs
6 (43) (all had EmA at
baseline)
6.5 (4-12)
years
Koskinen et al. 2008 ND, children
and adults
17 abdominal, 5 extraintestinal,
2 malabsorption, 4 asymptomatic
ND 13/21 increased
IELs, 25/26 IgA
deposits
28 (ND) (19 had ARA
or EmA+ at baseline)
1.7 (0.2-7.4)
years
ND, no data; ARA, antireticulin antibodies; AGA, antigliadin antibodies; EmA, endomysial antibodies; TG2-abs, tissues transglutaminase 2 antibodies; IELs,
intraepithelial lymphocytes
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Table 4. Studies involving patients who were placed on experimental gluten-free diet despite structurally normal small-bowel mucosal villi.
Baseline After gluten-free diet
Reference Patients Primary symptoms Serum antibodies
Mucosal
Histology Symptoms
Serum
antibodies
Mucosal
Histology
Cooper et al. 1980 17 adults 17 abdominal ND increased
IELs
alleviated
in 9/17
ND improved
in 8/12
Arranz and Ferguson
1993
9 adults 8 abdominal,
1 extraintestinal
ND 5/9 increased
IELs
alleviated
in 7/9
ND improved
in 3/5
Picarelli et al. 1996a 10 adults 7 abdominal,
3 extraintestinal
10/10 EmA,
7/10 AGA
4/10 increased
IELs
alleviated
in all
decreased
in all
improved
in 4/4
Kaukinen et al. 2001 10 adults 7 abdominal, 2 weight
loss, 1 extraintestinal
8/10 EmA,
9/10 TG2-abs
Marsh I-II alleviated
in all
decreased
in 9/9
improved
in all
Goldstein and
Underhill 2001
10 adults symptomatic 8/10 EmA,
5/10 AGA
structurally
normal
alleviated
in all
ND ND
Wahnscaffe et al.
2001
26 adults 26 abdominal 26/26 negative ND alleviated
in 17/26
ND improved
in 18/26
Tursi and
Brandimante 2003
23 adults 4 abdominal,
2 extraintestinal
3/23 EmA,
6/23 TG2-abs
Marsh I-II alleviated
in all
decreased
in 5/6
improved
in 5/6
Kakar et al. 2003 4 adults 3 abdominal,
1 anaemia
3/3 EmA, 1/3
TG2-abs
increased
IELs
alleviated
in all
ND ND
Järvinen et al. 2004  20 adults 13 abdominal, 1 anaemia,
1 extraintestinal, 5
asymptomatic
18/20 EmA 14/20 increased
CD3+ and 19/20
??+ IELs
alleviated
in all
decreased in
17/17
improved in
17/17
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Paparo et al. 2005 6 children 4 symptomatic 6/6 EmA increased CD3+
and ??+ IELs
alleviated
in all
decreased
in all
ND
Kaukinen et al. 2005 20 adults 18 abdominal, 1 anaemia,
1 asymptomatic
2/20 EmA,
5/20 TG2-abs
increased ??+
IELs, 4/20 IgA
deposits
ND ND IgA deposits;
lower intensity
in 3/4
Dickey et al. 2005 27 adults symptomatic 27/27 EmA Marsh 0-I alleviated
in 26/27
decreased
 in 26/27
ND
Koskinen et al. 2008 20 adults 17 abdominal, 1 anaemia,
2 extraintestinal
14/19 EmA or
ARA
18/20 increased
IELs, 20/20 IgA
deposits
alleviated
in 18/20
decreased
in 12/13
improved
in 13/18, 2 ND
Ludvigsson et al.
2009
30 children
and adults
abdominal symptoms in
most
17/30 EmA,
8/30 TG2-abs
structurally
normal
alleviated
in15/30
ND ND
IELs, intraepithelial lymphocytes; EmA, endomysial antibodies; AGA, antigliadin antibodies; TG2-abs; tissue transglutaminase 2 antibodies; ARA,
antireticulin antibodies; IgA deposits, tissue transglutaminase 2-targeted autoantibody deposits; ND, no data
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THE PRESENT STUDY
1. AIMS
With increasing knowledge of the variable phenotypes of coeliac disease it has come
to be recognized that small-bowel villous atrophy and crypt hyperplasia represent only
one of the many forms of the disorder. Nonetheless, the current diagnostic criteria for
coeliac disease are still based on the demonstration of these particular manifestations.
The main objective in the present study was to establish whether EmA-positive
subjects with normal small-bowel mucosal morphology suffer from a coeliac-type
disorder similar to that in patients already evincing diagnostic villous atrophy and
crypt hyperplasia.
The specific aims were:
1. Compare clinical, serological and histological markers and complications related to
coeliac disease in EmA-positive subjects with normal small-bowel mucosal structure
to those found in individuals with overt villous atrophy, and to non-coeliac controls (I-
III).
2. Establish whether early dietary treatment would be beneficial regardless of the
small-bowel mucosal morphology by dividing EmA-positive subjects either to
continue on a gluten-containing diet or to start an intervention with a gluten-free diet
(I-III).
3. Establish whether the intestinal and extraintestinal forms of coeliac disease can
fluctuate over time in the same patient on a gluten-containing diet  (IV).
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2. PATIENTS
2.1 Prospective studies (I-III)
All participants underwent clinical and serological evaluations and upper
gastrointestinal endoscopy in the Departments of Gastroenterology and Alimentary
Track Surgery (I-II) or Paediatrics (III) in Tampere University Hospital. Thereafter,
EmA-positive subjects continued in the studies and were further classified according to
the small-bowel mucosal morphology. The participants who had normal or non-coeliac
mucosal villous structure (Marsh 0-II) comprised the study groups, whereas those with
villous atrophy (Marsh III) comprised the coeliac disease control groups. The primary
reason for coeliac disease suspicion, the duration of symptoms, past medical history
and family history of coeliac disease were recorded in all cases at baseline.
Study I was a randomized trial. Altogether 145 adults were remitted to hospital
from primary health care due to clinical suspicion of coeliac disease. Ten patients
declined to participate and three cases were excluded by the presence of dermatitis
herpetiformis. None was on immunosuppressive medication. At baseline, extensive
clinical, serological and histological evaluations were carried out, thereafter EmA
positive subjects were classified into normal villi (Marsh 0-II) and villous atrophy
(Marsh III) groups as stated above. Next, patients with normal villous structure were
randomized either to receive normal gluten-containing diet or to start on an
experimental gluten-free diet. After one year the baseline investigations were repeated
in all the EmA-positive cases. Subsequently, a gluten-free diet was also offered to
those subjects who had been on a gluten-containing diet and a second follow-up visit
was arranged after another year (Figure 1 in original publication I). Altogether 34
EmA-negative adults who were investigated because of dyspepsia or heartburn were
used as non-coeliac controls for histological and serological evaluations. None of these
subjects had a family history of coeliac disease.
Study II was an unrandomized trial. Collection of data began during Study I and
the patients were to some extent the same with like inclusion criteria. Seven subjects
declined to participate and three cases with dermatitis herpetiformis were excluded.
None was using either immunosuppressive or antidepressive medication. Again, EmA-
positive patients were classified into the normal villi (Marsh 0-II) and villous atrophy
(Marsh III) groups; all subjects started a gluten-free diet. However, as 10 subjects in
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the study group belonged in the randomization protocol of Study I, they remained on a
gluten-containing diet for an additional year before the gluten-free diet was initiated
(Figure 1 in original publication II). Alongside the serological and histological
evaluations, self-rated gastrointestinal symptoms and health-related quality of life as
well as BMD and BMI were measured both at baseline and after one year on a gluten-
free diet. The non-coeliac controls for gastrointestinal symptom and health-related
quality of life comparisons were obtained from the Finnish Coeliac Society and
comprised a total of 110 adults who were friends or neighbours of coeliac patients and
had no coeliac disease suspicion.
The cohort in Study III comprised 59 EmA-positive children who were remitted to
hospital from primary health care due to suspicion of coeliac disease. None refused to
participate nor was immunosuppressive medication. After baseline investigations they
were divided into normal villi (Marsh 0-II) and villous atrophy (Marsh III) groups as
in studies I-II. Thereafter, children with positive EmA but normal villous structure
could either continue with a normal gluten-containing diet or start an experimental
gluten-free diet at the parents` decision. After one year all the EmA-positive
participants were re-investigated. However, as a second gastrointestinal endoscopy
after a year on gluten-free treatment is no longer recommended in children (Hill et al.
2005), it was performed only in those who continued gluten consumption. A total of
17 EmA-negative children and adolescents who were investigated because of
gastrointestinal symptoms or signs of malabsorption served as non-coeliac controls.
All had normal small-bowel mucosal villous structure.
2.2 Changing phenotype of coeliac disease (IV)
The material for Study IV comprised three cases who were investigated at the
Departments of Paediatrics, Gastroenterology and Alimentary Tract Surgery and
Dermatology in Tampere University Hospital between the years 1965-2005. All three
had suffered from classical gastrointestinal symptoms of coeliac disease during
childhood and at some point were found to have small-bowel mucosal villous atrophy.
However, as previously a separate gluten challenge was standard procedure to confirm
the diagnosis of coeliac disease (McNeish et al. 1979), in only one of these children
was the diagnosis confirmed and a gluten-free diet initiated, whereas in the other two
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cases a gluten-containing diet was resumed at puberty. While on challenge, one of
these developed villous atrophy and the diagnosis of coeliac disease was established,
whereas the other had normal villous structure even after three years on the gluten-
containing diet. Thereafter the follow-up of all three cases moved to primary care.
After a long asymptomatic period the subjects were remitted to the university hospital
with suspicion of dermatitis herpetiformis, and after clinical and serological
evaluations a skin biopsy and upper gastrointestinal endoscopy were performed in all
three cases.
3. METHODS
3.1 Small-bowel mucosal biopsy samples (I-IV)
The small-bowel mucosal biopsy specimens were taken from the duodenum upon
upper gastrointestinal endoscopy. The final processing and evaluation of the samples
were completed in the Paediatric Research Centre, University of Tampere. Depending
on the study in question, small-bowel mucosal morphology and inflammation (I-IV)
and TG2-specific autoantibody deposits (III-IV) were investigated in the mucosal
specimens. All the evaluations were made without prior knowledge of the past medical
history, dietary intervention, laboratory values or randomization group of the study
subjects.
3.1.1 Mucosal morphology and inflammation (I-IV)
Part of the biopsy specimens were paraffin-embedded and stained with haematoxylin
and eosin for morphometric analysis and part were snap-frozen in liquid nitrogen and
stored at -70ºC for further use. The small-bowel mucosal morphology was determined
from the paraffin specimens under light microscopy from three well-oriented sections.
Special attention was paid to the processing and orientation of the biopsy sections and
if necessary, the sections were dissected again until they were of sufficient quality. The
small-bowel mucosal lesion was scored according to Marsh (1992) as follows: in
Marsh 0 there are normal finger-like villi of a normal crypt depth and no excess of
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intraepithelial lymphocytes; in Marsh I-II intraepithelial lymphocytosis is seen in
normal villous structure without (Marsh I) or with (Marsh II) hyperplasic crypts, and
Marsh III comprises villous atrophy with crypt hyperplasia. The mucosal morphology
was further more precisely evaluated by measuring Vh/CrD as a mean of at least five
well-orientated villous-crypt pairs and a ratio <2.0 was regarded as compatible with
untreated coeliac disease (Kuitunen et al. 1982).
Immunohistochemical stainings were carried out on 5-µm-thick frozen sections
from three small-bowel mucosal biopsies. CD3+ IELs were stained with monoclonal
antibody Leu-4 (Becton Dickinson, San Jose, CA, USA), ??+ IELs with monoclonal
?F1 antibody (Endogen, Woburn, MA, USA) and ??+ IELs with T-cell receptor-?
antibody (Endogen). Positive IELs were counted with a X100 flat field light
microscope objective throughout the surface epithelium; at least 30 fields measuring
1.6 mm in epithelial length were counted and IEL density was expressed as cells/mm
of epithelium (Arranz et al. 1994). In our laboratory, the correlation coefficient for
intraobserver variation for CD3+, ??+ and ??+ IELs has been 0.95, 0.85 and 0.98, and
for interobserver variation 0.92. 0.82 and 0.98, respectively (Järvinen et al. 2003).
Small-bowel mucosal HLA DR expression was measured using monoclonal antibody
(Becton Dickinson, San Jose, CA) at a dilution of 1:1000. The expression was
considered normal when there was no staining in crypt enterocytes and only slight or
moderate expression in the villous epithelium. When any HLA-DR expression was
seen on the crypts or was strong in the villous epithelium, the expression was
considered enhanced (Arnaud-Battandier et al. 1986)
3.1.2 TG2-specific autoantibody deposits (III-IV)
IgA deposits were investigated in 5-?m-thick frozen sections by direct
immunofluorescence using fluorescein isothiocyanate-labelled rabbit antibody against
human IgA (DAKO AS, Glostrup, Denmark) at a dilution of 1:40 in phosphate-
buffered saline (PBS), pH 7.4. In the mucosa of untreated coeliac patients the
autoantibody deposit can be detected on extracellular TG2 below the basement
membrane along the villous and crypt epithelium and around mucosal vessels, whereas
in non-coeliac subjects IgA is detected only inside plasma and epithelial cells
(Korponay-Szabo et al. 2004). The co-localization of IgA deposits with TG2 was
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confirmed by double-staining the sections for human IgA and for TG2 using
monoclonal mouse antibodies against TG2 (CUB7402, NeoMarkers, Fremont, CA,
USA) and anti-mouse immunoglobulin antibodies (DAKO AS, Glostrup, Denmark). In
Study III the intensity of the deposits was graded semiquantatively on the basis of the
intensity along basement membranes and mucosal vessels in the villous-crypt area as
follows: negative, weak (+), moderate (++) and strong (+++) positive. In our
laboratory, the intraobserver and interobserver concordances in the detection of IgA
deposits have been 98% (Salmi et al. 2006b).
3.2 Serological tests (I-IV)
Serum IgA-class EmA values were determined by an indirect immunofluorescence
method using human umbilical cord as substrate, and a patient serum dilution of 1:5 or
more was considered positive (Ladinser et al. 1994). If positive, sera were further
diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. An enzyme-linked
immunosorbent assay (Celikey; Phadia, Freiburg, Germany) was used to investigate
the TG2-ab levels (I-III). The measurements were carried out according to
manufacturer’s instructions and values ?5.0 U were considered positive. In the case of
selective IgA deficiency (III) both the EmA and TG2-ab values were determined by
measuring corresponding antibodies in the IgG class (Sulkanen et al. 1998b,
Korponay-Szabo et al. 2003).
3.3 Laboratory parameters (I-II)
Laboratory measurements were made using the standard laboratory methods of
Tampere University Hospital. The following parameters were measured in EmA-
positive participants: serum albumin (age- and gender-specific reference values of the
hospital laboratory 36-48 g/L), serum iron (9-34 ?mol/L), red blood cell folate (200-
700 nmol/L) and serum vitamin B12 (150-740 pmol/L) (I); blood haemoglobin (men
134-167 g/L, women 117-155 g/L), serum ionized calcium (1.20-1.35 mmol/L) (I-II);
serum parathormone (1.6-6.9 ng/L), (1.20-1.35 mmol/L) and serum vitamin D1,25
(50-215 pmol/L) (II).
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3.4 Genetic markers (I-III)
The genetic studies to determine the coeliac disease-associated HLA DQ2 and DQ8
genotypes were performed either in the Department of Medical Genetics, University of
Helsinki, Finland (I-III) or in the Finnish Red Cross Blood Service Laboratory (I).
The HLA genotype was determined using  the DELFIAâ Celiac Disease Hybridization
Assay (PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland) (I-II),
and the SSPTM DQB1 low-resolution kit (I-II) (Olerup SSP AB, Saltsjöbaden,
Sweden/ Qiagen Vertriebs GmbH, Vienna, Austria) according to the manufacturer’s
instructions, or single-nucleotide polymorphisms tagging the coeliac disease-
associated HLA haplotypes as described by Monsuur and colleagues (2008) (III).
3.5 Clinical symptoms and quality of life (I-III)
In studies I and III, the researchers evaluated the gastrointestinal symptoms with
similar questions at each visit. In study I the symptoms were further classified into
four categories: no symptoms (0), slight symptoms (1) (occasionally one or more of
the following: abdominal pain, flatulence, diarrhoea, belching, tiredness or joint pain),
moderate symptoms (2) (symptoms more persistent, disturbing normal life), severe
symptoms (3) (severe daily symptoms significantly restricting normal life, or excessive
weight loss).
In study II the self-rated gastrointestinal symptoms were assessed using the
Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire (Svedlund et al. 1988)
and health-related quality of life by PGWB questionnaire (Dupuy 1984). The
questionnaires are well validated and widely used in coeliac disease research (Hallert
et al. 1998, Mustalahti et al. 2002, Usai et al. 2002, Hallert et al. 2002). The GSRS
questionnaire comprises 15 items covering five separate gastrointestinal symptoms:
diarrhoea, indigestion, constipation, abdominal pain and reflux. Rating is based on a
seven-grade Likert scale and higher scores indicate more severe symptoms. In the
PGWB questionnaire the 22 separate items comprise six sub-dimensions: anxiety,
depression, well-being, self-control, general health and vitality. The scoring is based
on a six-grade Likert scale, higher scores indicating better psychological well-being.
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3.6 Bone assessment and BMI
The BMD was measured at both the lumbar spine and left femoral neck using DEXA
(Sievänen et al. 1996). The density values were expressed as standard deviation scores
by comparing individual values either to the mean BMD of sex-matched healthy
young adults (T-score) or (subjects under 20 years of age) to that of the age- and sex-
matched population (Z-score). As defined by the World Health Organisation (WHO),
T-scores above -1.0 represented normal values, scores between -1.0 and -2.4
osteopenia and scores ?-2.5 osteoporosis (WHO 1994). If osteoporosis was detected,
bisphosphonate treatment together with supplementary calcium and vitamin D was
recommended for ethical reasons. Subjects who started this treatment were excluded
from subsequent statistical analyses. Body mass index (BMI) was computed as
weight/height2 (kg/m2). Values <18.5 were considered underweight, 18.5-24.9 normal,
25.0-29.9 overweight and >30.0 obese (WHO 1998).
3.7 Dietary assessment (I-III)
To ensure strict adherence to the diet, a trained dietitian advised all participants both at
baseline and at the end of each trial (I-III). In study III the children were counselled
together with their parents. If a patient was randomized to continue gluten
consumption (I), the target was to ensure approximately the average daily gluten
consumption, i.e 10-15 g of gluten/day (van Overbeek et al. 1997). Adherence to the
gluten-free diet was evaluated using combined information obtained from the dietary
evaluations, serological markers and histological measurements (I-III).
3.8 Statistical analyses (I-III)
Quantative data were expressed as means or medians and ranges (I-III), standard
deviations (I) or 95% confidence intervals (CI) (II). When appropriate, chi-square in
cross tabulations, two-tailed Student’s t-test or Mann-Whitney U test were used to
compare differences between groups at baseline (I-III) and paired t-test or Wilcoxon
signed rank test to compare changes within the groups (I-II). A two-tailed P value of
less than 0.05 was considered statistically significant. Randomization of the patients
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(I) was performed using random number tables with permuted blocks (Armitage and
Perry 1987).
3.9 Ethical considerations
The study protocols were approved by the Ethical Committee of Tampere University
Hospital. All subjects or their parents gave written informed consent.
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4. RESULTS
4.1 Patients in the intervention studies (I-III)
The demographic data on the participants are shown in Table 5. In Study I there were
altogether 70 EmA-positive subjects, of whom 23 had normal small-bowel mucosal
villous structure (Marsh I-II), while the remaining 47 had mucosal villous atrophy and
crypt hyperplasia (Marsh III). Ten subjects with Marsh I-II were randomized to
continue gluten consumption and 13 to start a gluten-free diet. In Study II, 27 out of
the 73 EmA-positive participants had Marsh I-II and 46 Marsh III. In Study III there
were 59 EmA-positive children, of whom three (18%) had completely normal mucosal
structure (Marsh 0), 14 (82%) had increased IELs (Marsh I) and the remaining 42
Marsh III. Altogether eight children with normal villi continued with a gluten-
containing diet and five started dietary treatment; four children moved to other health
care districts and were lost to the trial (Figure 1 in original publication III). In all three
studies EmA-positive subjects were comparable with respect to age, gender and family
history of coeliac disease regardless of the mucosal structure. The participants were
also comparable to the EmA-negative non-coeliac controls with respect to age and
gender (Table 5).
4.2 Small-bowel mucosal morphology and inflammation (I-III)
The results pertaining to the small-bowel mucosal Vh/CrD, IELs and HLA-DR
expressions before any dietary intervention are shown in Table 6. As defined in the
study protocol, the Vh/CrD was ? 2.0 in all EmA-positive participants considered not
to have coeliac disease and < 2.0 in all subjects with diagnosed coeliac disease. The
baseline levels of the IELs and the mucosal HLA-DR expression were comparable in
all EmA-positive participants regardless of the mucosal morphology, except the ??+
IELs, which were lower in subjects having normal villi in Study III. In contrast, these
inflammatory markers were significantly higher in the EmA-positive subjects than in
the EmA-negative controls (Table 6).
After the baseline investigations ten EmA-positive adults (Study I) and eight EmA-
positive children (Study III) with normal small-bowel mucosal villi remained on a
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gluten-containing diet. They were re-endoscopied after one year on trial and the
mucosal specimens revealed increasing mucosal deterioration in all adults (Figure 3)
and in all but one child (Table 2 in original publication III). In contrast, on a gluten-
free diet the Vh/CrD increased in all EmA positive subjects regardless of the small-
bowel mucosal morphology (Figure 3). Similarly, the IEL counts remained increased
after one year on a gluten-containing diet, whereas on a gluten-free diet all except ??+
IELs decreased significantly (Table 2 in original publication I). According to the study
protocol the EmA-positive children (Study III) were not re-biopsied while on a gluten-
free diet.
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Table 5. Demographic data, primary reason for coeliac disease suspicion and the human leukocyte antigen (HLA) type of the endomysial antibody (EmA)
-positive participants and EmA-negative non-coeliac controls in studies I-III
Study I Study II* Study III
EmA-positive cases  EmA-positive cases EmA-positive cases
 Normal villi†
Gluten GFD
Villous
atrophy
EmA-
negative
controls
Normal
villi
Villous
atrophy
EmA-
negative
controls
Normal
villi
Villous
atrophy
EmA-
negative
controls
Number of patients 10 13 47 34 27 46 110 17 42 17
Female, n (%) 6 (60) 9 (75) 41 (87) 21 (62)  18 (67) 40 (87) 89 (81)  10 (59) 25 (60) 10 (59)
Age, median
(range), years
53
(16-69)
49
(16-70)
43
(16-71)
53
(22-72)
48
(16-70)
42
(16-70)
49
(24-87)
11
(4-17)
10
(1-15)
11
(5-24)
Primary symptoms n (%)
Abdominal symptoms 8 (80) 10 (77) 25 (53) 34 (100)  19 (70) 25 (54) ND  13 (76) 26 (62) 15 (88)
Malabsorption 0 1 (8) 11 (23) 0  3 (11) 11 (24) ND  3 (18) 5 (12) 1 (6)
Extraintestinal symptoms‡ 0 1 (8) 5 (10) 0 1 (4) 5 (11) ND 0 6 (14) 1 (6)
Screening at-risk group§ 2 (20) 1 (8) 6 (13) 0  4 (15) 5 (11) ND 1 (6) 5 (12) 0
Duration of symptoms, median
(range), years
5
(0-50)
5
(0-40)
4
(0-50)
ND 3
(0-50)
4
(0-57)
ND 1
(0-2)
1
(0-4)
2
(0-4)
Coeliac disease in family, n (%) 5 (50) 5 (45) 16 (34) 0  13 (48) 16 (35) 0  8 (47) 20 (48) 4 (24)
HLA DQ2 or DQ8, n (%) 10 (100) 13 (100) 47 (100) 18 (53)  27 (100) 46 (100) ND  17 (100) 42 (100) 13 (65)
*Participants were partly the same as in Study I
†Patients were randomized either to a gluten-containing (Gluten) or a gluten-free (GFD) diet
‡Arthritis, dental enamel defects, neurological symptoms, elevated liver enzymes, aphthous stomatitis, gynaecological disorders, osteoporosis, poor growth
§Type I diabetes mellitus, autoimmune thyroid disease, Sjögren´s syndrome, family history of coeliac disease.
ND, no data
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Table 6. The baseline small-bowel mucosal villous height-crypt depth ratio (Vh/CrD), intraepithelial lymphocytes (IELs, cells/mm) and human
leukocyte antigen (HLA) -DR expression of the endomysial antibody (EmA) -positive participants and EmA-negative non-coeliac controls in
studies I-III
Study I Study II* Study III
EmA-positive cases EmA-positive cases EmA-positive cases
Normal
villi
Villous
atrophy
EmA-
negative
controls
Normal
villi
Villous
atrophy
EmA-
negative
controls
Normal
villi
Villous
atrophy
EmA-
negative
controls
Number of patients 23 47 34 27 46 110 17 42 17
Vh/CrD, median 2.6‡ 0.2‡ 3.4 2.2 0.2 ND 2.4† 0.2‡ 3.0
Range 2.0-3.6 0.1-1.9 2.8-5.2 2.0-3.6 0.1-1.3 ND 2.1-4.4 0.1-1.4 2.1-3.8
CD3+ IELs, median 62‡ 63‡ 32 62 64 ND 50‡ 80‡ 28
Range 37-134 34-124 11-62 37-134 34-124 ND 22-64 28-124 14-64
??+ IELs, median 37† 45‡ 24 37 45 ND 21 57‡ 25
Range 16-63 14-104 7-47 16-63 14-104 ND 9-57 20-94 9-68
??+ IELs, median 19.1‡ 19.5‡ 2.1 19.2 17.9 ND 18.7‡ 21.9‡ 2.1
Range 7.0-51.8 5.9-54.6 0.0-24.8  7.0-51.8 5.9-54.6 ND  7.7-41.3 7.6-47.9 0.7-7.7
HLA-DR expression
Enhanced n (%) 21 (96)‡ 42 (100)‡ 18 (53)  25 (96) 44 (100) ND  16 (94) 42 (100)‡ 12 (71)
Normal 1 (0) 0 (0) 16 (47) 1 (4) 0 (0) ND 1 (6) 0 (0) 5 (29)
*Participants were partly the same as in Study I
†P <0.05 compared to EmA-negative controls
‡P <0.001 compared to EmA-negative controls
ND, no data
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Figure 3. The small-bowel mucosal villous height-crypt depth ratio (Vh/CrD) (A) and
serum endomysial (EmA) (B) and transglutaminase 2 (TG2) (C) antibodies at baseline
and after one year on a gluten-containing (Gluten) or gluten-free (GFD) diet in the
EmA-positive participants in studies I and III.
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4.3 Serology, laboratory parameters and genetics (I-III)
By definition, all participants in the study groups were EmA-positive. The TG2-abs
were positive in 14 (61%) out of 23 (Study I), 17 (63%) out of 27 (II) and 15 (88%)
out of 17 (III) of those with normal small-bowel mucosal villous structure. The
corresponding figures for patients with Marsh III were 44 (94%) out of 47 (I), 43
(93%) out of 46 (II) and 40 (95%) out of 42 (III). Both the EmA titres and the TG2-ab
values were significantly lower in participants having normal villi than in those with
Marsh III (P < 0.001 (I, II); P = 0.002 (III)). One subject in Study III was IgA-
deficient, but the corresponding antibodies in IgG class were positive. None of the
EmA-negative non-coeliac controls had positive TG2-ab values. While on a gluten-
containing diet (I, III), the EmA titres and TG2-ab values remained or increased in
almost all subjects having normal villous structure (Figure 3). In contrast, on a gluten-
free diet the antibodies decreased in all subjects regardless of the mucosal morphology.
The EmA titres and TG2-ab values either disappeared or decreased likewise in all
participants in Study II.
In Study I, the haemoglobin and iron values were significantly higher in the EmA-
positive subjects with Marsh I-II than in those with Marsh III. In participants with
normal villi none of the laboratory parameters changed significantly during the dietary
interventions, whereas in subjects with Marsh III the haemoglobin, folate and vitamin
B12 increased significantly during the gluten-free diet (Table 3 in original publication
I). In Study II the mean haemoglobin level was significantly higher in subjects
evincing normal mucosal structure than in those with Marsh III (P=0.004). Three
patients with Marsh I-II and 12 with Marsh III had parathormone values above
reference values. On a gluten-free diet the abnormal parathormone values improved in
all of these except for two cases with Marsh III, and the haemoglobin also increased in
all subjects (n=9) having anaemia at baseline.
All EmA-positive participants in studies I-III had the coeliac disease-associated
HLA DQ2 or DQ8 genotype irrespective of the small-bowel mucosal villous
morphology, whereas 18 (53%) out of 34 non-coeliac controls in study I and 13 (76%)
out of 17 in study III were DQ2- or DQ8- positive (Table 5).
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4.5 Clinical evaluation (I-III) and quality of life (II)
The primary clinical symptoms leading to suspicion of coeliac disease are shown in
Table 5. The nature and duration of the symptoms and the number of asymptomatic
subjects were comparable in EmA-positive participants irrespective of the degree of
small-bowel mucosal damage. When the EmA-positive participants with normal
villous structure continued gluten consumption the symptoms remained basically
unaltered, whereas on a gluten-free diet they either disappeared or were alleviated in
almost all subjects regardless of the mucosal structure (Figure 3 in original publication
I and Table 2 in original publication III).
There were no differences in the GSRS total or sub-dimension scores between the
Marsh I-II and Marsh III groups, except  for a higher frequency of diarrhoea in the
latter (Study II). However, the participants in both EmA-positive groups had
significantly more diarrhoea, indigestion, abdominal pain and reflux than the non-
coeliac controls (Table 2 in original publication II). On a gluten-free diet the
indigestion score in the Marsh I-II and the total and all sub-dimension scores in the
Marsh III group decreased significantly (Figure 2 in original publication II). The
differences in the PGWB total or sub-dimension scores were not significant between
the EmA-positive study groups and the non-coeliac controls at baseline. While on a
gluten-free diet the depression score in the Marsh I-II group and total, self-control and
general health scores in the Marsh III group improved significantly (Figure 3 in
original publication II).
4.6 Bone assessment and BMI (II)
At baseline, 11 (58%) out of 19 subject with EmA but normal villi had either
osteopenia (47%) or osteoporosis (11%). The mean Z-score was -0.1 (95% CI -0.5 to
0.4) for the lumbar spine and 0.1 (-0.4 to 1.0) for the femoral neck. Of the Marsh III
subjects 20 (51%) out of 39 had osteopenia and eight (21%) osteoporosis, and the
mean Z-scores were -0.6 (-1.0 to -0.1) for lumbar spine and -0.3 (-0.6 to -0.1) for
femoral neck. After the year on a gluten-free diet the BMD was re-measured in the 10
subjects with normal villi, and although BMD increased in most of them, the changes
were not statistically significant (Figure 4 in original publication II). In the Marsh III
group BMD increased significantly in both the lumbar spine and femoral neck.
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The BMI was within normal range in 11 (41%) out of 27 subjects with Marsh I-II,
12 cases (44%) were overweight and four (15%) obese. In the Marsh III group one
patient (2%) was underweight, 23 (55%) were normal-weight, 10 (24%) overweight
and eight (19%) obese. Differences between the groups or changes within the groups
while on treatment were not statistically significant.
4.7 Changing phenotype of coeliac disease (IV)
All three patients in this study had an itching bullous rash suggestive of dermatitis
herpetiformis, whereas none had significant gastrointestinal symptoms (Figure 4). The
asymptomatic period from the last endoscopic investigations ranged from 13 to 18
years, and during this time the subject with negative gluten challenge (Case 2) had
remained on a gluten-containing diet and in the other two cases dietary treatment had
been incomplete. Skin biopsy of all three cases showed granular IgA deposits in the
dermal papillae of the perilesional skin, confirming the diagnosis of dermatitis
herpetiformis. Although at some point they all had gastrointestinal presentation and
small-bowel mucosal villous atrophy, at the time of the dermatitis herpetiformis
diagnosis there was no intestinal symptoms and only partial villous atrophy in the
mucosa.  In addition, all cases had either positive ARA or EmA in the serum. The
small-bowel mucosal TG2-specific IgA deposits were also measured from frozen
sections and all three patients evinced clear coeliac-type deposition (Figure 2 in
original publication IV). Subsequently all three patients were again placed on a strict
gluten-free diet, with a good clinical response and negative seroconversion of the
coeliac antibodies.
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6 years: abdominal
pain, villous atrophy
16 years: asymptomatic,
normal villi, gluten challenge
35 years: rash
on elbows
19 years: asymptomatic,
normal villi
CASE 2.
CASE 1.
5 years: abdominal
pain, villous atrophy
17 years: asymptomatic,
normal villi, gluten challenge
18 years: villous
atrophy, ARA 1:500
31 years: rash on
elbows and knees
CASE 3.
34 years: rash on elbows,
knees and pubic area
6 months: poor
growth, vomiting
10 months: poor growth,
vomiting, anaemia
16 years: delayed puberty, abdominal
pain, villous atrophy, ARA 1:200
Figure 3. The medical history of the three patients in Study IV. Black bars = gluten-
containing diet; white bars = gluten-free diet; dashed bars = partial gluten-free diet.
ARA, antireticulin antibodies
4.8 Dietary choices after the trial (I-III)
After the trials were completed, all the EmA-positive participants in studies I-III were
considered to suffer from a gluten-dependent disorder regardless of the small-bowel
mucosal morphology. Thus, a gluten-free diet was offered, and either at their own (I-
II) or by their parents (III) decision all continued on treatment.
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5. DISCUSSION
5.1 Problems with the current histological criteria
The diagnostic criteria for coeliac disease have developed together with an increasing
understanding of the natural history of the disorder. As the decision to start out on life-
long treatment has to be based on firm evidence, the first criteria required altogether
three separate intestinal biopsies to ensure the gluten-dependency of the patients
(Meeuvisse 1970). As a result, the diagnostic protocol was particularly burdensome
and long drawn-out. In addition, it was eventually discovered that mucosal recovery
while on treatment might take several years (Grefte et al. 1988), and on the other hand,
the histological relapse while on a gluten challenge could emerge much later than the
two years required for the diagnosis (Kuitunen et al. 1986). These observations led in
1990 to the establishment of new and simplified diagnostic criteria (Walker-Smith et
al. 1990). Nevertheless, demonstration of small-bowel mucosal villous atrophy was
still required and the few recent updates have not markedly changed this situation
(United European Gastroenterology 2001, Hill et al. 2005).
Unfortunately, substantial problems attend this histology-based definition of coeliac
disease. The mucosal lesion can be patchy along the whole length of the small intestine
and might be missed even if several biopsies are taken (Scott and Losowsky 1976).
Furthermore, imprecise slicing or wrong orientation of the biopsy samples may yield
erroneous results and, even if properly processed, the final analysis of the specimens is
always somewhat subjective (Collin et al. 2005a). Importantly, none of the currently
known histopathologic markers is pathognomic for coeliac disease as such (Kuitunen
et al. 1975, Spencer et al. 1991, Iltanen et al. 1999b, Kakar et al. 2003, Lähdeaho et al.
2005). Finally, the current diagnostic criteria focus mainly on the classical
gastrointestinal disorder and ignore extraintestinal forms of coeliac disease such as
dermatitis herpetiformis.
Apart from histological assessment, another question has been the role of the
coeliac antibodies in the diagnosis. The first serological markers of coeliac disease
were discovered as far back as the early 1970s (Seah et al. 1971, Carswell and
Ferguson 1972), but their specificity was considered insufficient for a definitive
diagnosis (Unsworth et al. 1983), although later the IgA-class ARA showed excellent
results in an experienced laboratory (Mäki et al. 1984b). Furthermore, although the
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highly specific EmA were already established by Chorezelski and associates in 1983,
they were widely accepted only after human tissue could be used as substrate; that is,
after the current diagnostic criteria were launched (Ladinser et al. 1994). The
establishment of the TG2-ab tests a few years later (Dieterich et al. 1998, Sulkanen et
al. 1998a) practically revolutionized the diagnostic approach, but thus far the role of
the autoantibodies in the diagnosis of coeliac disease has remained mainly supportive
(United European Gastroenterology 2001, Hill et al. 2005).
5.2 Coeliac disease without villous atrophy
The previous section emphasized the technical problems and unsolved questions
related to the diagnosis of coeliac disease, but the situation became even more
challenging when it was discovered that the characteristic small-bowel mucosal
damage develops gradually (Mäki et al. 1990, Mäki et al. 1991a, Marsh 1992). This
observation and the fact that patients may be symptomatic while still having villi
indicate that the current diagnostic criteria should be revisited (Kaukinen et al. 2001).
Although mild mucosal changes are an unspecific finding as such (Kuitunen et al.
1982, Lähdeaho et al. 2005), it has been suggested that the more specific EmA and
TG2-abs could be used for early diagnosis when the villous structure is still normal
(Kaukinen et al. 2001, Dickey et al. 2005, Paparo et al. 2005, Koskinen et al. 2008).
However, firm evidence for new criteria has been lacking and the present series (I-III)
were the first controlled, prospective clinical studies to evaluate the natural history and
effect of a dietary intervention in subjects having positive EmA but normal small-
bowel mucosal structure.
5.2.1 Histology, serology and genetic markers
To obtain objective results, the small-bowel mucosal morphology was evaluated using
the Vh/CrD as described by Kuitunen and associates (1982). Interestingly, although
the Vh/CrD was by definition ³2.0 in all EmA-positive adults and children evincing
normal villi, the ratios increased even further while these subjects were on a gluten-
free diet, and thus the “normal” small-intestinal mucosa improved even further. In
contrast, on a gluten-containing diet the Vh/CrD decreased in almost all EmA-positive
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subjects; in fact, many of them developed villous atrophy (Figure 3A). These results
demonstrated that both the development of the mucosal damage and its recovery are
gradual and gluten-dependent processes. Based on these findings, there is no clear
morphological cut-off line which would separate EmA-positive “non-coeliac” patients
from those with gluten-sensitive disease. Since villous damage may also appear in
conditions other than coeliac disease (Kuitunen et al. 1982, Green and Cellier 2007), it
seems that these structural changes have limited value in the diagnosis at least of
borderline cases.
The small-bowel mucosal inflammation was measured using several different
histological markers of coeliac disease. In adults the CD3+ and ??+ IELs and the
mucosal HLA-DR expression were comparable between the EmA-positive groups, but
differed markedly from the EmA-negative controls. Furthermore, the IELs showed
clear gluten-dependent responses during the dietary interventions. Although in
children the CD3+ and ??+ IELs were higher in those with villous atrophy than in
those having normal villi, the cell densities were still increased in both groups when
compared with the EmA-negative controls. The results demonstrated that, similarly to
the morphological changes, the development of the mucosal inflammation is a gradual
and gluten-dependent process. Nevertheless, consistent with previous studies there was
substantial overlapping between EmA-positive and EmA-negative participants,
showing again that these inflammatory markers are too unspecific for the diagnosis as
such (Kuitunen et al. 1982, Järvinen et al. 2003, Kakar et al. 2003, Salmi et al. 2010).
In contrast, the increased density of the mucosal ??+ IELs is a much more specific
finding (Spencer et al. 1991, Järvinen et al. 2003) and the high density of these cells in
EmA-positive subjects with normal villi gives further evidence for the presence of a
coeliac-type disorder. However, even the ??+ IELs were elevated in some EmA-
negative subjects, and since they may appear without coeliac-type HLA (Iltanen et al.
1999b), it is evident that they are not pathognomic for coeliac disease. In addition, as
also noted in previous studies (Järvinen et al. 2003 and 2004), the ??+ IELs showed a
rather slow and inconsistent response to the dietary treatment. Given that special
methods and a frozen sample are required for their determination, it would seem that
the ??+ IELs seldom provide any additional benefit in EmA-positive cases.
Irrespective of the mucosal morphology, the serum EmA titres showed indisputable
gluten-dependent responses to the dietary interventions, again emphasizing the
similarity of the antibody-positive participants. In addition, the TG2–abs showed a
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strong correlation to the EmA levels and evinced corresponding responses to the
gluten-free diet. This was quite as expected, since both antibodies are targeted against
TG2 (Korponay-Szabo et al. 2003) and have shown similar specificity figures in
previous studies (Table 2). Besides the antibodies in serum, the coeliac-type intestinal
IgA deposition was present in all the EmA-positive children but in none of the
seronegative controls (Study III). Since the deposits have been shown to be highly
specific for forthcoming coeliac disease (Korponay-Szabo et al. 2003, Kaukinen et al.
2005, Salmi et al. 2006b, Koskinen et al. 2008), their presence in the EmA-positive
children was a very strong indicator of a coeliac-type disorder.
 Despite similar responses to the dietary interventions, the EmA titres and TG2-ab
values were significantly lower in subjects with normal villi than in those having
villous atrophy. This is consistent with recent findings by Donaldson and associates
(2007), where the antibody levels were also lower in children with normal villi than in
those having Marsh III. Furthermore, Abrams and colleagues (2004) have shown that
subjects having partial villous atrophy are more often seronegative than those with
completely flat mucosa. The reason for these differences is unclear, but it is of note
that both here and in a study by Koskinen and colleagues (2008) the intensity of the
mucosal IgA deposits correlated with the degree of enteropathy. These results suggest
that the reason for the lower serum autoantibody levels in patients with normal villi is
reduced intestinal production. Finally, regardless of the small-bowel mucosal
morphology, all the EmA-positive subjects here had either the HLA DQ2 or the DQ8
genotype. Since these haplotypes are practically a requirement for coeliac disease,
their presence gives further evidence that all these EmA-positive participants belonged
to the genetically gluten-sensitive population (Sollid et al. 1989, Mäki et al. 2003,
Karell et al. 2003).
5.2.2 Clinical evaluation, quality of life and dietary compliance
The clinical symptoms were evaluated both by the researchers and using structured
questionnaires and, except for diarrhoea, they were comparable irrespective of the
small-bowel mucosal morphology. Similarly, the laboratory values were mostly at the
same level regardless of the villous structure. This rather small correlation between the
clinical presentation and the degree of enteropathy was somewhat unexpected, as it
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would seem logical that patients with villous atrophy would have more symptoms.
However, there are also previous studies showing no obvious correlation between the
clinical symptoms and the degree of  mucosal damage (Brar et al. 2007, Murray et al.
2008, Table 3). Instead, it has been suggested that the extent of the intestinal
involvement would determine the clinical severity of coeliac disease (Marsh and
Crowe 1995), but even this hypothesis has recently been questioned (Murray et al.
2008). Nevertheless, there were still differences between the EmA-positive groups in
diarrhoea and some laboratory parameters. This is in line with findings by a group
under Donaldson (2007), who noted that EmA-positive children with normal villi had
less diarrhoea than those with Marsh III. It could thus be speculated that only the
malabsorptive symptoms are directly related to the villous damage, while most of the
clinical symptoms are caused by other factors. In any case, the results confirmed
previous findings that EmA-positive subjects may suffer from clinical symptoms and
benefit from dietary treatment while still having normal mucosal morphology
(Kaukinen et al. 2001, Paparo et al. 2005, Dickey et al. 2005, Salmi et al. 2006).
In the past few decades the self-assessed quality of life has gained increasing
attention in medical research, since it provides information as to how a particular
disease affects the daily lives of patients (Yacavone et al. 2001). This is especially
important in coeliac disease, where the treatment involves life-long and demanding
dietary restriction. It was somewhat surprising that no significant differences were
observed between the EmA-positive participants having either normal villi or villous
atrophy and the non-coeliac controls. Nonetheless, there was a trend towards poorer
PGWB scores in the EmA-positive groups and it is possible that their number was too
small for the results to reach statistical significance. Alternatively, general
questionnaires such as PGWB might not be sensitive enough to reflect minor
abnormalities and more disease-specific instruments might have been needed (van
Doorn et al. 2008). The assumption that these subjects still had reduced quality of life
is supported by the fact that some of the PGWB subscores improved significantly
during the dietary intervention. Particularly the reduction in depression in subjects
with normal villi was important, since depression has a been common finding in
untreated coeliac disease and may also reduce dietary compliance (Ciacci et al. 1998,
Ludviggson et al. 2007, Nachman et al. 2009). The fact that none of the PGWB
subscores decreased in the EmA-positive groups further supports the overall benefits
of a gluten-free diet. Finally, it must be emphasized that according to the current
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criteria these EmA-positive and symptomatic subjects would have to undergo regular
and burdensome endoscopic studies and long-term follow up until villous atrophy
develops.
In contrast to some other studies (Högberg et al. 2003, Whitaker et al. 2009), the
dietary compliance of the EmA positive participants was excellent throughout the
present series. Although it is possible that those who participated were more willing to
start the treatment than those who declined, good dietary compliance has been a
frequent finding also in other Finnish studies of coeliac disease (Viljamaa et al. 2006).
These results may be partly explained by the high prevalence of diagnosed cases and
the generally good knowledge about coeliac disease in Finland (Virta et al. 2009).
Furthermore, the availability of gluten-free products from groceries is good and
biopsy-proven patients obtain monthly financial support from the Social Insurance
Institution. In any case, the present study showed that good dietary compliance can be
achieved irrespective of the small-bowel mucosal structure.
5.2.3 Bone assessment and BMI
As expected in the light of previous studies (Caraceni et al. 1988, Valdimarsson et al.
1994, Corazza et al. 1995b), the baseline BMD was significantly decreased in subjects
with small-bowel mucosal villous atrophy. Nevertheless, decreased BMD was also
noted in many EmA-positive subjects with normal villi. This is in accord with other
recent studies suggesting that coeliac disease can predispose to osteoporosis even prior
to the development of villous atrophy (Kaukinen et al. 2001, Tursi et al. 2003, Dickey
et al. 2006, Esteve et al. 2006). The reason for this reduction in BMD is obscure, but a
similar tendency to osteoporosis has also been observed in patients suffering from
inflammatory bowel disease, indicating that chronic intestinal inflammation might
have an adverse effect on bone mineral accrual (Taranta et al. 2004, Tilg et al. 2008).
Although the clinical relevance of the decreased BMD is unclear, the fact that subjects
with villous atrophy are at significantly increased risk of bone fractures (Vasquez et al.
2000, West et al. 2003a) suggests that early-initiated treatment might lower this risk in
such patients. In addition, delayed treatment of coeliac disease in childhood
predisposes to permanent disturbances in bone maturation and growth, further
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emphasizing the importance of early diagnosis (Barr et al. 1966, Mora et al. 1999, Tau
et al. 2006).
Contrary to the classical picture of “withered” coeliac disease patients, the EmA-
positive subjects evinced a proneness to overweight regardless of the mucosal
morphology. In fact, a tendency towards obesity similar to that in the general
population has also been observed in other recent studies of coeliac disease (West et al.
2004b, Viljamaa et al. 2005, Dickey and Kearney 2006). The observation may reflect
the changing pattern of coeliac disease, as nowadays patients often have milder clinical
symptoms at diagnosis than previously (Mäki et al. 1988a, Green and Cellier 2007).
Interestingly, there was no difference in the EmA-positive groups in either the mean
BMI between the groups or within the groups during the gluten-free diet. These results
are somewhat contradictory to those obtained by Dickey and Kearney (2006), where
subjects with severe villous atrophy had significantly lower BMI than those with
milder mucosal damage, and even overweight patients gained more weight while on
treatment. Although these disparities may be partly explained by the smaller number of
cases in the present series, the results still suggest that a gluten-free diet is not
necessarily detrimental to the weight control of coeliac patients.
5.3 Genetic gluten intolerance
While the prospective studies here (I-III) demonstrated that EmA positive subjects
have a similar gluten-dependent disorder irrespective of the villous morphology, Study
IV showed that the clinical and histological phenotype of coeliac disease can change
over time. At some point all three patients in this group had gastrointestinal symptoms
and overt villous atrophy, but at the time of their skin relapse they had only skin
symptoms and partial villous atrophy in the mucosa. In addition, in one case the
villous structure was normal after three years on gluten challenge, showing that there
can be long periods of histological latency. It is well known that the mucosal damage
in dermatitis herpetiformis may be variable (Marks et al. 1966, Savilahti et al. 1992,
Reunala 2001), but hitherto the natural history of the histological changes has
remained unclear. However, it has been shown that identical twins may have
disconcordance in the clinical and histological presentation, with intestinal disease in
one and dermatitis herpetiformis in the other sibling (Hervonen et al. 2000).
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Interestingly, all three cases also had positive ARA or EmA in the serum and TG2-
targeted IgA deposition in the small-bowel mucosa, again showing that the
autoantibodies are the integrative feature in the distinct forms of coeliac disease.
Furthermore, the presence of the autoantibodies is a very early phenomenon in the
disease process (Korponay-Szabo et al. 2004, Simell et al. 2007) and there is
increasing evidence that they also have an important role in the pathogenesis
(Halttunen and Mäki 1999, Esposito et al. 2002, Barone et al. 2007, Myrsky et al.
2008).  It has since been speculated that after being produced in the intestine the
antibodies may enter the circulation and participate in the extraintestinal
manifestations of coeliac disease (Korponay-Szabo et al. 2004, Lindfors et al. 2009).
For example, subjects with autoantibodies against TG3 could develop dermatitis
herpetiformis (Sardy et al. 2002) and subjects with those against TG6 gluten ataxia
(Hadjivassiliou et al. 2008b). The same patient could still have antibodies against TG2
and simultaneous intestinal disease or even fluctuating phenotype, as in Study IV.
Such a conception is supported by the fact that subjects with dermatitis herpetiformis
diagnosed in adulthood may have coeliac-type permanent tooth enamel defects,
suggesting that some form of gluten sensitivity has been present in early childhood
(Aine 1996).
These results indicate that both the intestinal and extraintestinal forms of coeliac
disease share the same genetic background, dependency on dietary gluten and initial
intestinal pathogenesis with or without a manifest mucosal lesion. Thus, instead of
coeliac disease, the term genetic gluten intolerance might be more descriptive for the
wide spectrum of these disorders. Interestingly, already in the 1990s a so-called
“cooking-pot” model of coeliac disease was presented by Mäki (1992). In this model
the intestine is the primary “pot” for the pathogenetic events, and the clinical
manifestations are the end-result of the genetic predisposition, gluten exposure and
other environmental factors (Kaukinen et al. 2007b). In 1997 Mäki and Collin also
suggested using the term coeliac trait for this broadened view of gluten-dependent
disorders. The results of the present series and the knowledge of the extraintestinal
forms of coeliac disease accruing in recent years provide further evidence for this
model (Figure 5).
Besides changing phenotype, the clinical relapses in Study IV occurred after a
particularly long asymptomatic period. This is consistent with other findings indicating
that the histological and clinical relapse may take even decades despite continuous
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gluten consumption (Kuitunen et al. 1986, Högberg et al. 1993, Matysiak-Budnik
2007). This is important, since the increasing serological screening often reveals cases
with positive antibodies but no other signs of coeliac disease and it is still debated
whether some cases could remain in permanent latency (Simell et al. 2007, Matysiak-
Budnik et al. 2007). Accordingly, there was also one child in Study III in whom the
mucosal structure remained normal despite a gluten-containing diet. Then again, her
coeliac antibodies persisted and it is possible that she will develop either villous
atrophy or more severe clinical symptoms in the future. However, for the moment the
natural history of the EmA-positive but asymptomatic cases with normal villi is
unclear and only careful follow-up can be recommended (Simell et al. 2010).
Genetic
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immunology
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factors
GLUTEN
Small-bowel
mucosal
changes
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Figure 5. The cooking pot of coeliac disease. The development of coeliac disease
requires a complex interaction between genes, environmental factors and the
immunological system of the gut. Although the small intestine is the principal site for
the pathogenetic mechanisms, the mucosal lesion represents only one entity among the
various clinical manifestations of genetic gluten intolerance. Adapted from Mäki 1995
and Kaukinen et al. (2007b).
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5.4 Limitations of the study and future challenges
Certain important issues should be considered when interpreting the results of this
study. First, there was a small number of subjects who either refused to participate or
were excluded from the studies, and in theory they might have affected the results
obtained. In addition, for ethical reasons the paediatric study was conducted as a non-
randomized follow-up trial. However, no significant difference in either clinical
symptoms, antibody levels or histological markers was observed between the children
who remained on a normal diet and those who started the dietary intervention (Table 2
in original publication III). Any risk that gender distribution might have affected to the
results is unlikely, since the groups were comparable in this respect and the apparent
over-representation of females is characteristic of coeliac disease (Green et al. 2001).
The use of highly specific EmA as an inclusion criterion was fairly straightforward,
but there are certain problems related to the use of the immunofluorescence method.
First, it is laborious and time-consuming and thus unpractical for large-scale screening
studies. Secondly, the interpretation of the specimens is inevitably subjective, which
may in borderline cases comprise a risk of a wrong negative or positive result. The
positive EmA staining can also be masked by the presence of other serum
immunoglobulins such as anti-smooth muscle antibodies (Sulkanen et al. 1998b).
Finally, the good accuracy of EmA is shown primarily in subjects with a high pre-test
probability of coeliac disease, and those having mild symptoms or lesser degrees of
mucosal damage may yield poorer results (Rostami et al. 1999, Abrams et al. 2004).
For the aforementioned reasons it is essential that only well-validated laboratories and
qualified personnel are used if EmA positivity is to constitute a diagnostic criterion for
coeliac disease.
In contrast to EmA, TG2-abs can be measured using a practical and objective
ELISA method, and it would be tempting to generalize the results of the present study
to include subjects with positive TG2-abs. Indeed, most of the EmA-positive
participants had positive TG2-abs and their gluten-dependency was shown by
measuring both antibodies. On the other hand, as the TG2-abs are often used as a first-
line screening method, it has been essential to obtain maximal sensitivity at the
expense of optimal specificity. Furthermore, the accuracy of the commercial TG2-ab
assays seems to be somewhat variable and method-dependent (Villalta et al. 2005,
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Hopper et al. 2007). Consequently, the results of this study should not be applied to
subjects having only positive TG2-abs.
Most of the EmA-positive participants in the present study had clinical symptoms
and only few were screen-detected asymptomatic subjects. As a consequence, the
results can not be generalized to subjects having positive EmA and normal villi but no
symptoms. This is problematic, since serological screening has revealed that
asymptomatic subjects may actually represent a substantial proportion among coeliac
patients (Mäki et al. 2003, Fasano et al. 2003, Korponay-Szabo et al. 2007). In fact,
although a gluten-free diet is recommended to asymptomatic patients with villous
atrophy, no randomized studies have ever been undertaken and actual evidence for
their treatment is scant (Hill et al. 2005). Nevertheless, as there is some evidence that
they may benefit from the dietary treatment, it has been speculated whether even
population-based screening for coeliac disease would be justified (Mustalahti et al.
1999, Viljamaa et al. 2004, Fasano 2009). Evidently, more studies are needed, but at
present it seems reasonable that at least patients with any symptoms or signs of
coeliac-disease associated complications should be treated regardless of the clinical
presentation (Collin 2005b).
Finally, the results lead to the inevitable question whether a small-bowel biopsy is
necessary for all subjects with positive EmA and clinical symptoms. In fact, the need
for histological confirmation of the diagnosis was questioned soon after the excellent
specificity of EmA for coeliac disease was observed (Valdimarsson et al. 1996). Our
results show that EmA-positive patients have a similar gluten-dependent disorder and
should be treated regardless of the degree of the mucosal damage, and it would seem
logical that at least some of these subjects could be diagnosed without histological
confirmation. Nevertheless, the present study was not designed to evaluate the role of
endoscopic studies in the diagnostics. In addition, there were only a few cases with
completely normal mucosa and the possible benefits of the dietary treatment in these
subjects calls for further confirmation. Thus, in the future more randomized studies are
needed to assess the role of intestinal biopsy in the diagnosis of coeliac disease.
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6. SUMMARY AND CONCLUSIONS
The present study demonstrated that the current diagnostic criteria for coeliac disease
are inadequate to cover the wide clinical spectrum of the gluten-dependent disorders.
Firstly, the prospective studies (I-III) showed that EmA positive subjects may suffer
from the clinical symptoms and even complications of untreated coeliac disease
irrespective of the small-bowel mucosal morphology. Furthermore, the gluten
dependency of these subjects was demonstrated using several histological, clinical and
serological markers. The results confirmed the hypothesis that villous atrophy
represents only the end-point in the gradual development of the histological changes in
coeliac disease. It was also observed that none of the currently known histological
markers, for example CD3+ and ??+ IELs or mucosal HLA-DR expression, is  specific
for an early developing disease. Based on our results, at present determination of
serum EmA and intestinal TG2-targeted IgA deposits is the most accurate diagnostic
method for coeliac disease.
The result of Study II showed that early intervention with a gluten-free diet was
detrimental for neither the quality of life nor the weight control of the EmA-positive
subjects with normal villi. Furthermore, there was a trend towards increasing BMD
values in these participants, suggesting that early treatment might at least prevent the
development of more severe osteoporosis. These findings are important, since life-long
treatment with gluten-free diet can be restrictive and difficult to maintain, and it was
essential to show that early treatment is not harmful for the daily life of these EmA-
positive participants. The conclusion that the dietary treatment was beneficial was
further supported by the fact that irrespective of the degree of villous damage, all
EmA-positive participants continued on a gluten-free diet when the trials were
completed.
Finally, the results of Study IV demonstrated that both the histological and the
clinical presentation of coeliac disease can fluctuate over time, and that even the
complete phenotype of the disorder may change from intestinal to extraintestinal. The
fact that all three patients had positive serum autoantibodies and TG2-targeted mucosal
IgA deposits constitutes further evidence that the two forms of coeliac disease are
merely different phenotypes of the same gluten-dependent disorder.
In conclusion, the present study confirmed that small-bowel mucosal villous
atrophy is not the optimal golden standard for coeliac disease and that there are a
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substantial number of patients who have an indisputable gluten-sensitive disorder
while still evincing normal mucosal morphology. Furthermore, the intestinal and
extraintestinal forms of coeliac disease are only different variations of the same gluten-
dependent disorder. Based on the findings here, in symptomatic subjects having only
inflammatory changes in the small-bowel mucosa EmA positivity  represents a
sufficient and highly specific marker of a genetic gluten-sensitive disorder. In the
future, more prospective studies are needed to elucidate the natural history of EmA-
positive subjects who manifest no clinical symptoms and those with completely
normal intestinal mucosa. Also, randomized studies are required to assess whether the
coeliac autoantibodies can completely replace the conventional histology in the
diagnosis of the disorder.
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